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Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by loss 
of tolerance to nuclear antigens and tissue destruction. While the sources of autoantigens in SLE 
are unknown, release of contents from dying cells and/or inadequate clearance of resulting debris 
are likely possibilities.  
Prior reports suggest that neutrophil extracellular traps (NETs) and its associated death 
pathway, NETosis, are sources of autoantigen in SLE. However, we showed that inhibition of 
NETs by targeting the NADPH oxidase complex, via Cybb-deletion, exacerbated disease in the 
MRL.Faslpr model of SLE. To clarify the contribution of NETs in SLE pathogenesis, we 
employed a genetic approach to delete peptidyl arginine deiminase IV (Padi4) and neutrophil 
elastase (Elane), two distal mediators of NET formation, in MRL.Faslpr mice. Both Padi4 and 
Elane deficiency did alter disease course, directly challenging the concept that NETs promote 
autoimmunity.  
Therefore, it remains unknown how NADPH oxidase regulates autoimmunity. NADPH 
oxidase can constrain inflammation by neutrophil, macrophage, and lymphocyte dependent 
mechanisms. To identify the cell lineage in which Cybb deficiency drives SLE, we employed 
bone marrow chimera and conditional knockout approaches to delete Cybb in the myeloid 
compartment of MRL.Faslpr mice. Myeloid Cybb deficiency is sufficient to worsen glomerular 
and interstitial nephritis, suggesting that Cybb is protective in SLE due to a fundamental 
regulatory activity of Cybb within the myeloid compartment. 
THE ROLE OF NADPH OXIDASE AND NEUTROPHIL EXTRACELLULAR TRAPS 
IN THE PATHOGENSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS 
Rachael A. Gordon, B.A. 
University of Pittsburgh, 2017
 
 v 
NADPH oxidase is a critical mediator of LC3-associated phagocytosis (LAP), which is 
important for the clearance of dead cells by macrophages. As Cybb modulates SLE pathogenesis 
by its function in myeloid cells, we assessed LAP in lupus. To test the hypothesis that 
exacerbated SLE in Cybb-deficient mice is due to defective LAP, we genetically deleted another 
critical LAP mediator, Rubicon, in Cybb-sufficient and Cybb-deficient SLE prone mice. 
Unexpectedly, Rubicon deficiency increased the lifespan and ameliorated renal disease in Cybb-
deficient MRL.Faslpr mice. Strikingly, Rubicon deficiency reduced the autoantibody responses to 
RNA associated autoantigens. These data suggest that a defect in LAP is not a major driver of 
SLE and highlights RUBICON as a novel mediator of lupus pathogenesis. The mechanism by 
which myeloid Cybb regulates SLE remains enigmatic and requires further investigation.  
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1.0  INTRODUCTION 
Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease featuring renal, 
dermatological, musculoskeletal, hematological, cardiac, pulmonary, and neurological 
manifestations (1). Predominantly targeting women of childbearing age, the estimated incidence 
and prevalence of SLE of lupus in the United States is 5.1 and 52.2 per 100,000 people 
respectively (2). The direct annual costs to SLE patients range from $29,034-$62,651 for those 
with nephritis to $12,273-$16,575 for those without renal manifestations of SLE impacting their 
quality of life (3). SLE is treated with broad immunosuppressive agents, autophagosome-
lysosome fusion inhibitors, and biologics targeting B cells. Belimumab (Benlysta), a monoclonal 
antibody that targets B cell activating factor (BAFF), was the first drug to be FDA approved for 
the treatment of patients with SLE in nearly 50 years (2). More recently, monoclonal antibodies 
targeting type I interferons (IFN) and their corresponding receptor are in clinical trials and show 
promising therapeutic benefit (4, 5). Despite these advances, current therapeutics are not curative 
and are riddled with adverse effects, contributing to the morbidity and mortality of this patient 
population. Understanding the underlying immunological mechanisms that mediate SLE 
pathogenesis will provide insight into how the immune system constrains the response to self and 
uncover targets for therapeutic development that address the unmet needs of this patient 
population. 
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1.1 NUCLEIC ACID SENSING IN SLE 
SLE is characterized by the formation of autoantibodies to nucleic acids and the proteins to 
which these nucleic acids associate. Loss of tolerance to self results in immune activation and 
tissue destruction. Innate immune sensing of self nucleic acids and nucleoproteins is implicated 
in the initiation and progression of SLE. Endosomal Toll-Like Receptors (TLRs) or cytoplasmic 
DNA and RNA sensors can detect foreign nucleic acids from invading pathogens but also have 
the capability to recognize self DNA and RNA. The mechanism by which exogenous nucleic 
acids enter immune cells is unclear but may involve the MHC class III molecule, RAGE. 
1.1.1 TLRs and SLE 
The endosomal TLRs, TLR7 and TLR9, are important in the pathogenesis of SLE. Indeed, 
polymorphisms in TLRs and their signaling adaptors are associated with SLE. While TLR9 
canonically recognizes bacterial CpG DNA and TLR7 detects viral ssRNA, endosomal TLRs can 
be activated by endogenous ligands (Figure 1) (1). The development of autoantibodies in lupus is 
dependent on endosomal TLRs, with TLR9 and TLR7 requisite for the generation of antibodies 
to DNA and RNA associated autoantigens respectively (2, 3). The function of individual 
autoantibody subsets in SLE remains elusive. While nucleic acid sensing is critical for 
autoantibody formation, the global role of TLR7 and TLR9 in disease pathogenesis is 
diametrically opposed; Tlr7 deficiency ameliorates disease while Tlr9 deficiency exacerbates 
disease in multiple murine models of systemic autoimmunity (3-10). Mirroring these 
observations, overexpression of Tlr7 worsens clinical and immunological manifestations of SLE 
in the Tlr7 transgenic system and in the Yaa model of murine lupus where a portion of the Y 
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chromosome harboring Tlr7 is duplicated (5, 6). Tlr7-/yTlr9-/- MRL.Faslpr SLE prone mice are 
protected from the clinical manifestations of lupus and lack autoantibodies to DNA and RNA 
related antigens (2). MYD88 is a critical signaling adaptor for both TLR7 and TLR9. 
Concordantly, genetic deletion of Myd88 phenocopies Tlr7-/ -Tlr9-/- SLE susceptible mice (2). 
These findings implicate TLRs, and not other receptors that use MYD88, as the major regulators 
of SLE pathogenesis. The role of TLRs in the clinical manifestations of lupus is likely cell 
specific. While Myd88 deficiency in B cells ameliorates renal disease and autoantibody 
production, Myd88 deletion in dendritic cells (DCs) abrogates dermatitis without impacting other 
manifestations of lupus (11). The cell specific function of the endosomal TLRs in SLE remains 
enigmatic and requires further investigation.  
1.1.2 Cytosolic DNA sensors and SLE 
The function of cytoplasmic DNA and RNA sensors in SLE is less well characterized. The 
detection of cytosolic RNA is attributed to three helicases that serve as RNA sensors including 
retinoic acid‐inducible gene (RIG-I), melanoma differentiation-associated gene 5 (MDA5), and 
laboratory of genetics and physiology 2 (LGP2) (12-14) (Figure 1). While RIG-I recognizes viral 
single stranded RNA (ssRNA), double stranded RNA (dsRNA) with 5’ triphosphates or 
diphosphates and short dsRNA, MDA5 detects long blunt dsRNAs (15-18). LGP2 facilitates 
recognition of RNA viruses by RIG-I and MDA5 but does not contain a caspase activation and 
recruitment domain (CARD) requisite for downstream signaling (14, 19). RIG-I and MDA5 
signal via the mitochondrial anchored adaptor mitochondrial antiviral signaling protein (MAVS) 
resulting in the activation of tank binding kinase 1 (TBK1) (20). TBK1 induces nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB) dependent proinflammatory cytokine 
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production and phosphorylates interferon regulatory factor (IRF) 3 and IRF7 allowing for their 
hetero- and homo-dimerization and translocation to the nucleus where IRFs serve as transcription 
factors to mediate IFN transcription (21-23). Stimulator of interferon genes (STING) is required 
for optimal type I IFN production by RIG-I but not MDA5 (24). Recently, mitochondrial reactive 
oxygen species (ROS) were implicated in MAVS oligomerization and subsequent type I IFN 
production in SLE patients (25). A gain of function polymorphism in MDA5 (A946T) is 
associated with SLE (26-29).  Moreover, IRF3 promoter polymorphisms that result in reduced 
IRF3 expression are reported to confer protection from SLE (30). However, in the MRL.Faslpr 
mouse model of SLE, Irf3 deficiency does not alter manifestations of autoimmunity (31).  
Cytosolic sensing of DNA can occur through a variety of different receptors and 
downstream signaling mechanisms (Figure 1). Strikingly, cytosolic DNA sensors do not mandate 
a specific DNA sequence nor are impacted by DNA methylation status that is unique to 
pathogens. Therefore, cytosolic DNA sensors have the capacity to respond to self DNA. DNA-
dependent activator of IRFs (DIA) was one of the first receptors suggested to recognize cytosolic 
DNA (32). However, DIA-deficient mice were still able to generate type I IFNs in response to 
cytosolic DNA suggesting the existence of additional cytosolic DNA sensors (33). More 
recently, guanosine monophosphate adenosine monophosphate synthase (cGAS), IFN inducible 
protein 16 (IFI16), and the DExD/H family of helicase DDX41 have been recognized as 
cytosolic DNA sensors that converge on the STING pathway as a central hub (24, 34-36). DNA-
dependent RNA polymerase III can sense and transcribe AT-rich dsDNA and the resulting 
dsRNA product initiates the RIG-I pathway (37, 38).  
There are several lines of evidence that link cytosolic DNA sensing to systemic 
autoimmunity. DNase II and III (3′ repair exonuclease 1, Trex1) are important for the 
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degradation of endogenous DNA (39) (40). Loss of function polymorphisms in DNASE II and 
TREX1 are associated with SLE (41-43). Mice and humans with DNASE II and TREX1 
deficiency are not able to degrade endogenous DNA, resulting in a rampant type I IFN response 
and autoinflammation (39-42). Patients with Aicardi Goutières syndrome, characterized by loss 
of function mutations in TREX1, develop severe neurological impairment and debilitating SLE-
like autoimmunity (42). In mice, the inflammatory syndrome observed in the setting of Trex1 
deficiency is STING dependent. DNase II-/- mice that are crossed to the interferon-α/β receptor 
(IFNAR) knockout allele to prevent embryonic lethality caused by type I IFN induced anemia, 
develop inflammatory arthritis that is both dependent on STING and the absent in melanoma 2 
(AIM2) inflammasome (44, 45). Similarly, gain of function mutations in TMEM173, the gene 
that codes for STING, can result in autoinflammation. Patients with STING-associated 
vasculopathy with onset in infancy (SAVI) exhibit increased IFNβ production and rampant 
inflammation that results in tissue damage (46, 47). Discordant with these observations, STING-
deficient MRL.Faslpr mice develop markedly accelerated SLE, manifesting in decreased survival, 
worsened renal disease, and higher titers of autoantibodies. In this setting, STING controls the 
expression of critical innate signaling regulators (31). The multiple facets of STING in systemic 
autoimmunity require further exploration. 
The inflammasome is also implicated in cytosolic DNA sensing as AIM2 is activated by 
cytosolic DNA (48-50). Upon DNA sensing, AIM2 complexes with apoptosis-associated speck-
like protein containing a CARD (ASC) to form the AIM2 inflammasome. Inflammasome 
activation triggers caspase-1 dependent proteolytic processing of the inflammatory cytokine 
Interleukin (IL)-1β into its active form (49, 50). Moreover, the AIM2 inflammasome initiates 
pyroptosis, an inflammatory form of programmed cell death, in macrophages (51). Indeed, AIM2 
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is found within SLE susceptibility loci and AIM2 expression (52) is elevated in macrophages 
from male SLE patients (53). However, our group genetically deleted Asc, a central adaptor for 
most inflammasomes complexes, including AIM2, and found no effect on disease in MRL.Faslpr 
mice (54). It is possible that inflammasomes that function independent of ASC are important for 
SLE pathogenesis but these data preclude a role for AIM2 in the MRL model of SLE.  
1.2 THE SOURCE OF AUTOANTIGEN IN SLE 
While sensing of self nucleic acids and nucleoproteins is critical for SLE pathogenesis, the 
source of these autoantigens is still unknown.  One possibility is that dying cells could be this 
source. The mechanism by which a cell dies may have critical implications on the host response 
to resulting debris by revealing ligands to nucleic acid sensors and/or altering the environment in 
which these endogenous ligands are detected. Apoptosis is a non-immunogenic caspase 
dependent programmed cell death pathway whereby the proteolytic cascade leads to cleavage of 
cellular proteins and DNA (55). Successful apoptosis produces fewer damage associated 
molecular patterns (DAMPs) and induces production of the immunoregulatory cytokines  IL-10 
and Transforming Growth Factor β (TGFβ) from phagocytic macrophages (55). Subsequent 
release of “eat me” and “find me” signals, such as calreticulin and phosphatidylserine (PS), leads 
to clearance of cell corpses by macrophages (56).The role of dead cell clearance and associated 
production of immunoregulatory cytokines in SLE is the subject of chapters 3 and 4. Impaired 
clearance of apoptotic cells can  promote secondary necrosis (55, 57). Necrosis or programmed 
necroptosis is an immunogenic form of cell death characterized by cytoplasmic swelling, 
membrane rupture, and organelle degradation. Receptor-interacting protein (RIP) Kinases and 
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the terminal effector MLKL mediate the formation of the necrosome composed of Caspase 8, 
RIP1, and RIP3 (55, 58, 59). Necroptosis has been associated with kidney transplant rejection 
(60). Pyroptosis is another form of catastrophic cell death that results from caspase 1 dependent 
pore formation and rapid plasma membrane lysis, releasing cellular contents, IL-1β, and IL-18 
(51, 55). Ferroptosis is a more recently defined mechanism associated with iron dependent 
oxidation of polyunsaturated fatty acids (PUFA) and resultant cell death (61). 
 
In 2004, Brinkmann and colleagues first described a process whereby neutrophils can 
release DNA coated with antimicrobial peptides and proteases into the extracellular space 
forming structures that we now refer to as neutrophil extracellular traps (NETs) (62). Neutrophil 
death resulting from NET generation is termed suicidal NETosis. NET formation is generally 
dependent on Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase generated ROS 
(63, 64). Peptidyl arginine deiminase 4 (PADI4), an enzyme which citrullinates histones 
requisite for chromatin decondensation (65, 66), is an important conserved mediator for NET 
formation. Though reports suggest that NETs are a source of antigenic nucleic acids in SLE (67-
74), we and others have recently shown that inhibition of classical NETs by genetically deleting 
critical components of the NADPH oxidase complex, including Cytochrome b-245, β 
polypeptide (Cybb), exacerbates multiple manifestations of SLE in several murine models  (75-
77). The role of critical distal NET mediators, such as Padi4 and neutrophils elastase (Elane), in 
SLE is the topic of chapter 2.  The mechanism by which NADPH oxidase deficiency drives SLE 
pathogenesis will be addressed in chapters 3 and 4.  
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1.3 THE MRL.FASLPR MODEL OF SLE 
To study the causative impact of a gene or biological process in a disease setting, it is important 
to have a model system that can be both genetically manipulated and recapitulates pathology 
observed in patients. The MRL.Faslpr model of SLE is a leading system for the study of lupus 
since it has the advantage of being driven by multiple genes of the MRL background coupled 
with spontaneous onset, as in the case of human SLE (78). Fas-deficiency accelerates the disease 
but is not required for it, nor does it generally impact outcomes of genetic or therapeutic 
manipulations (78). MRL.Faslpr mice typically develop clinical features of SLE and 
lymphoproliferation by 16-weeks of age. Notably, the MRL model recapitulates nearly all 
American College of Rheumatology diagnostic criteria (75, 79) and is both type I/type II IFN-
dependent (80, 81). On multiple occasions, observations first obtained with MRL.Faslpr were 
later confirmed in Fas-sufficient MRL mice. Therefore, we used MRL.Faslpr mouse model of 
SLE in the studies that we present here as this strain allows for a comprehensive analysis of 
multiple relevant disease parameters. 
1.4 SPECIFIC AIMS 
The source of autoantigen remains an important and unresolved question in the study of SLE 
with major implications in our understanding of autoimmune pathogenesis and strategies towards 
therapeutic intervention. While the sources of autoantigens in SLE are not known, two leading 
possibilities include (1) the release of antigenic contents from dying cells and/or (2) subsequent 
failure to adequately dispose of resulting debris by macrophages. 
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While exacerbated SLE in the context of NADPH oxidase deficiency challenges the idea 
that NETs promote lupus, it is conceivable that global regulatory properties of NADPH oxidase 
and NADPH oxidase independent NETs confound these findings. Indeed, there are multiple 
reported means by which NADPH oxidase can inhibit inflammation (82, 83), including 
neutrophil (84, 85), macrophage (86), and lymphocyte (87, 88) dependent mechanisms. 
Recently, NADPH oxidase function was found to be required for LC3-associated phagocytosis 
(LAP) (89). LAP has been linked to the concurrent production of suppressive rather than pro-
inflammatory cytokines and mice incapable of performing LAP develop autoimmunity (90). This 
line of investigation will be further addressed in chapters 3 and 4.  
The overarching hypotheses of this thesis are: (1) NETs are not the primary source of 
autoantigen in SLE and (2) NADPH oxidase exerts a fundamental regulatory activity in the 
myeloid compartment by modulating neutrophil death and or dead cell clearance by 
macrophages. These hypotheses will be addressed in the following specific aims:  
  
Specific aim 1: Evaluating the role of NETs in SLE by knocking out Padi4 or Elane in 
lupus prone mice. 
 
Specific aim 2: Investigating the cell specific role of NADPH oxidase in the pathogenesis of 
SLE by employing chimera and conditional knockout approaches in a mouse model of 
lupus. 
 
Specific aim 3: Assess the contribution of LAP by genetically deleting Cybb, Rubicon, and 
myeloid IL-10 in the MRL.Faslpr mouse model of SLE. 
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Figure 1. Endosomal Toll-like receptors and sensors of cytosolic nucleic acids.  
Adapted from: Crowl JT, Gray EE, Pestal K, Volkman HE, and Stetson DB. Intracellular Nucleic Acid Detection in 
Autoimmunity. Annual Review of Immunology. 2017;35(1):313-36. 
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2.0  NEUTROPHIL EXTRACELLULAR TRAPS AND SLE: EVALUATING THE 
ROLE OF PEPTIDYL ARGININE DEIMINASE 4 AND NEUTROPHIL ELASTASE IN 
THE PATHOGENESIS OF LUPUS 
Adapted from: Gordon RA, et al. Lupus and proliferative nephritis are PAD4 independent in 
murine models. JCI Insight. 2017;2(10) 
2.1 INTRODUCTION 
SLE is a systemic autoimmune disease characterized by the formation of autoantibodies to 
nucleic acids and the proteins to which these nucleic acids associate. Loss of tolerance to self 
results in immune activation and tissue destruction. While the sources of autoantigens in SLE are 
not known, the liberation of antigenic contents from dying is considered a likely culprit.  
2.1.1 Neutrophil extracellular traps 
NETs are extruded DNA structures coated with granular and cytoplasmic contents that are 
released into the extracellular environment. It is conceivable and compelling that NETs could be 
a source of autoantigen in SLE and a downstream mediator of end-organ damage. At least one 
billion neutrophils die per kilogram of body weight each day, underscoring the neutrophil as a 
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potential antigen source (91). Early studies proposed that NETs are composed of decondensed 
nuclear DNA and that the neutrophil dies upon NET release (64). More recently, nuclear DNA 
externalization without concomitant cell lysis (92) and extrusion of mitochondrial DNA (93-95) 
have been described. Classical NET formation in humans and mice is dependent on NADPH 
oxidase-generated reactive oxygen species (ROS) (63, 64), though rapid NADPH oxidase-
independent NET formation has been reported (92, 96).  
2.1.2 Peptidyl arginine deiminase 4 and NETs 
Peptidyl arginine deiminases (PADI) are a family of calcium dependent enzymes that catalyze 
the conversion of arginine to citrulline (97).  There are 5 PADI members in mouse and humans, 
PADI1-4 and PADI6, each with differential tissue distribution and cellular localization (97). 
PADI4 is predominantly expressed in granulocytes and resides in the nucleus where it can 
deaminate histones (98). The physiological functions of PADIs are not well characterized. 
PADI4 dependent histone citrullination is associated with transcriptional regulation (99, 100). 
Antibodies towards citrullinated peptides are associated with systemic autoimmune diseases 
including rheumatoid arthritis and SLE (101-103). Importantly, PADI4-dependent histone 
citrulluation facilitates chromatin decondensation a conserved step in NET formation (65, 66, 
104-107). PADI4 is critical for the generation of NETs (65, 66, 104-107). Neutrophils from 
Padi4-deficient mice fail to make NETs (65, 66) and pharmacological inhibition of PADI4 with 
potent and specific PADI4 inhibitors, GSK199 and GSK484, reduced NET formation in mouse 
and human neutrophils (106).  
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2.1.3 Neutrophil Elastase and NETs 
Neutrophil elastase (ELANE) is a serine protease representing 5% of the total protein content in 
NETs, second to histones (108, 109). Many groups report that ELANE is not only a structural 
component of the NET but crucial for their formation in mice and humans (107, 110-113). Upon 
activation, ELANE is released from the azurophilic granules and translocates to the nucleus in a 
NADPH-oxidase and myeloperoxidase (MPO)- dependent manner (111, 112). Production of 
H2O2 allows for disassociation of ELANE from a membrane bound complex into the cytosol 
(111, 112). During this process, ELANE binds F-actin in the cytoplasm and degrades it to 
translocate to the nucleus (111). In the nucleus, ELANE initially degrades H1 followed by H4 
histones, the latter of which is associated with decondensation of nuclear DNA (111, 112). 
Recently, neutrophils derived from a patient with a novel loss of function polymorphism 
(G210R) in exon 5 of ELANE were shown to exhibit defective NET formation (110). 
Interestingly, this mutation did not confer congenital neutropenia but the patient did exhibit 
inflammatory arthritis and recurrent parvovirus infections (110).  
Several lines of indirect evidence link ELANE as an important mediator of NET 
formation. Protease inhibitors can prevent NET formation, including the ELANE inhibitors, 
secretory leukocyte protease inhibitor (SLPI) and Serpin Family B Member 1 (SERPIN1b) (114, 
115). Neutrophils from Slpi-deficient mice are more efficient at generating NETs both in vitro 
and in the context of a murine psoriasis model in vivo (115). Serpin1b-deficient neutrophils have 
a greater propensity to form NADPH oxidase-dependent and -independent NETs in response to 
various stimuli in vitro (114). Moreover, NET generation of serpin1-deficient neutrophils is 
increased in the setting of Pseudomonas aeruginosa lung infection (114). Papillon-Lefèvre 
syndrome (PLS) is characterized by mutations that inactivate cysteine protease Cathepsin C 
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(CTSC) which processes a variety of serine proteases into an active state, including ELANE 
(116). Neutrophils from PLS patients undergo reduced NET formation (116, 117).  
2.1.4 NETs and SLE 
Several lines of evidence suggest that NETs may be a primary and non-redundant source of self-
antigen in SLE. NET-like structures are found in the skin and kidneys of SLE patients and SLE 
prone mice (67-70), while NET degradation is impaired in a minor subset of individuals with 
lupus (71, 72). Abnormal low density granulocyte (LDGs) populations identified in a peripheral 
blood mononuclear cell (PBMC) fractions isolated from SLE cohorts have an increased 
propensity to form NETs in vitro, potentially enhancing exposure to autoantigens and 
immunostimulatory molecules (67, 73). Neutrophils from SLE patients can activate plasmacytoid 
dendritic cells (pDC) to produce type I IFN upon culture in vitro, a phenomenon attributed 
specifically to NET formation (68, 74). Concordantly, anti-ribonuclear protein (RNP) antibodies, 
which are present in a subgroup of SLE patients, can induce in vitro NETs from SLE but not 
normal neutrophils, in a process dependent on FcγRIIA, ROS, and TLR7 (68). Activating Fcγ 
receptors (FcγRs) are critical for the pathogenesis of SLE nephritis (118), and neutrophil FcγRs 
promote renal injury (119) leading to the possibility that FcγR mediated NET formation 
contributes to end organ injury. More recently, two groups reported that anti-RNP antibodies and 
immune complexes (IC) can induce the externalization of immunostimulatory oxidized 
mitochondrial DNA (94, 95). While SLE LDGs release oxidized mitochondrial DNA (95) and 
anti-oxidized mitochondrial DNA autoantibodies (94) are elevated in pediatric SLE patients, the 
mechanism by which oxidized mitochondrial DNA is released in the context of SLE, its 
relationship to NET-like structures, and its role in disease pathogenesis remains controversial.   
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While the above data tend to associate NETs with SLE pathogenesis, this concept is 
challenged by murine studies in which classical NETs were abolished by genetically deleting 
Cybb, an essential component of the NADPH oxidase complex, in the context of a lupus-prone 
genetic background (75). In these mice, not only was lupus still present but Cybb-deficiency 
exacerbated multiple manifestations of lupus and immune activation, including kidney disease. 
These results parallel prior observations in male chronic granulomatous disease (CGD) patients 
who carry an X-linked mutation in CYBB (120), as well as their carrier mothers (121, 122).  
These individuals have higher, not lower, incidences of spontaneous autoimmunity. Furthermore, 
alleles of other components of the NADPH oxidase complex, neutrophil cytosolic factor (NCF) 1 
and 2, that are thought to be less functional, are positively associated with lupus across multiple 
ethnic groups (123-125). Although these studies argue against the hypothesis that NETs drive 
lupus, it remains possible that other immune dysregulatory effects of global Cybb-deficiency 
dominantly override the requirement for NADPH oxidase driven NETs in this case. In addition, 
as there have been reports that various stimuli induce distinct types of NETs, it is possible that 
CYBB-independent NET formation could drive SLE. 
To address this pivotal controversy, it is important to evaluate independent approaches to 
block NET generation in the setting of SLE. PADI4 and ELANE are natural targets since 
neutrophils from Padi4- and Elane-deficient mice fail to make NETs (65, 66). We chose to 
eliminate Padi4 and Elane in the MRL.Faslpr strain as it has been tested in both the context of 
Cybb-deficiency and PAD pharmacological inhibition (69, 70, 75), thus allowing for direct 
comparison of results. Importantly, inhibitors targeting the NET pathway will enter clinical 
trials, underscoring the need for a better understanding of their targets in NET formation and the 
in vivo consequences of their use.  
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Here, we show that abrogation of Padi4 and Elane by a genetic approach did not have 
any impact on clinical or immunological parameters of SLE in MRL.Faslpr. Taken together with 
earlier work (75), these findings challenge the concept that NETs, to the degree that NET 
generation relies on PADI4 (65, 66, 104-107, 126), ELANE (107, 110-113), or CYBB (63, 64, 
127-129), critically drives lupus and nephritis. 
2.2 SYSTEMIC LUPUS ERYTHEMATOSUS IS INDEPENDENT OF PADI4 IN THE 
MRL.FASLPR MURINE MODEL 
To assess the role of Padi4-deficiency in SLE, we backcrossed the Padi4-/- allele onto the 
MRL.Faslpr background for 9 generations. Heterozygous mice were then intercrossed to produce 
an experimental cohort. SLE pathology was analyzed at 17 weeks of age.  
2.2.1 Padi4-deficiency did not affect nephritis or dermatitis 
No differences in urine protein were detected in the fully backcrossed cohort (Figure 2A). Padi4-
deficiency had no impact on dermatitis (Figure 2B). No statistically significant differences in 
glomerulonephritis or interstitial nephritis were detected among the different Padi4 genotypes in 
either cohort (Figure 2C and D).  Similarly, Padi4 genotype did not impact splenomegaly and 
lymphadenopathy (Figure 2E and F).  
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2.2.2 Padi4-genotype had no impact on loss of tolerance or the anti-self responses 
Padi4-genotype did not generally alter the autoantibody response or Ig titers. We did not detect 
any change in anti-RNA antibody (Figure 3A), anti-Sm antibody (Figure 3B), anti-nucleosome 
antibody (Figure 3C), rheumatoid factor (RF) (Figure 3D), or total IgM (Figure 3E) and total IgG 
titers (Figure 3F) in the context of Padi4-deficiency. Concordant with these data, there were no 
statistically significant differences in total kappa Ig antibody forming cell (AFC) ELISpots 
(Figure 4A). Similar AFC ELISpot results were obtained for the IgG1, IgG2a, and IgM isotypes 
(Figure 4-D). Furthermore, Padi4-genotype did not affect the percentage of CD19+ B cells 
(Figure 4E) or CD19low-int CD44+ CD138+ intracellular κhigh AFCs (Figure 4F).  
2.2.3 Padi4-deficiency did not change the myeloid compartment 
Padi4-genotype had only a minor impact on the myeloid compartment in MRL.Faslpr mice. The 
percentages of CD11b+Ly6G+ bone marrow (BM) neutrophils (Figure 5A) and 
CD11b+F4/80+Gr1low-int BM macrophages (Figure 5B) were not statistically different among the 
groups. Female Padi4-/- mice had a greater percentage of splenic neutrophils compared to their 
heterozygous counterparts (Figure 5C). Additionally, no change in CD11b+F4/80+Gr1low-int 
macrophages were identified across Padi4 genotype (Figure 5D).  No differences in the 
percentage of CD19-CD11c+MHCII+ conventional DCs (cDCs) (Figure 6A and B) and CD19-
BST2+ SiglecH+ pDCs (Figure 6A and C) were identified among the groups. 
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2.2.4 Padi4-deficiency did not alter the lymphoid compartment 
Padi4-deficiency did not substantially impact the lymphoid compartment. All genotypes 
exhibited indistinguishable total percentages of TCRβ+ T cells (Figure 7A and B). The 
percentages of CD4+ T cells and CD4+CD44+CD62L- activated T cells were also similar amongst 
wild-type, Padi4-deficient, and heterozygous mice (Figure 7A and C). Similar results were 
obtained for naive and activated CD8+ T cells (Figure 7A and D).  
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Figure 2. Padi4-genotype did not impact lupus nephritis, dermatitis, or lymphadenopathy/splenomegaly. 
(A) Proteinuria. (B) Dermatitis scores. (C) Glomerulonephritis scores. (D) Interstitial nephritis scores. (E) Spleen 
weight. (F) Axillary lymph node weights. Scores and weights are represented as a function of Padi4-genotype and 
gender at 17 weeks of age. Bars represent the median and each dot represents and individual mouse. A Kruskal-
Wallis test with post-hoc Dunn’s test was performed to determine statistical significance within each gender (* 
indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=8 to 22 mice per group). 
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Figure 3. Padi4-genotype did not significantly alter the anti-self response. 
(A-F) Serum anti-RNA (A), anti-Sm (B), anti-nucleosome (C), rheumatoid factor (D), and total IgM (E) and total 
IgG (F) antibody titers at 17 weeks of age. The dotted line denotes the upper limit of quantitation. Data 
representation, number of mice, and statistics are as in Figure 2.  
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Figure 4. Padi4 deficiency did not change the AFC compartment. 
(A-D) Numbers of Igκ (A), IgG1 (B), IgG2a (C), and IgM (D) antibody forming cells (AFCs) per spleen as 
determined by ELISpot. (E) B cell gating strategy (top panel) and the percentages of live CD19+ total B cells 
(bottom panel). (F) AFC gating strategy (top panel) and the percentages of live cells that are TCRβ− CD44+ CD138+ 
intracellular κ+ in spleens (bottom panel). Data representation, number of mice, and statistics are as in Figure 1. In 
panels E and F, bar graphs are represented as the mean ± SEM and a one-way ANOVA with post-hoc Holm-Sidak 
test was performed to determine statistical significance within each gender (* indicates p≤0.05, ** p≤0.01, *** 
p≤0.001, and **** p≤0.0001; n=8 to 22 mice per group).   
 22 
 
Figure 5. Padi4-genotype did not substantially affect the myeloid compartment. 
(A) Bone marrow (BM) neutrophil gating strategy (top panel) and the percentages of live BM CD11b+ Ly6G+ 
neutrophils (bottom panel). (B) BM macrophage gating strategy (top panel) and the percentages of BM CD11b+ 
GR1low-int F4/80+ macrophages (bottom panel).  (C) Splenic neutrophil gating strategy (top panel) and the 
percentages of live CD11b+ Ly6G+ neutrophils in the spleen (bottom panel). (D) Splenic macrophage gating strategy 
(top panel) and the percentages of splenic CD11b+ GR1low-int F4/80+ macrophages (bottom panel). Bar graphs are 
represented as the mean ± SEM and a one-way ANOVA with post-hoc Holm-Sidak test was performed to determine 
statistical significance within each gender (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=8 to 
22 mice per group).   
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Figure 6. Dendritic cells populations were not impacted by Padi4 deficiency. 
(A) Conventional (cDC) and plasmacytoid (pDC) dendritic cell gating strategy. (B) Percentages of live CD19- 
MHCII+ CD11c+ cDCs and (C) CD19- BST2+ CD11c+ pDCs. Data representation, number of mice, and statistics are 
as in Figure 5. 
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Figure 7. Padi4 deficiency had little impact on the lymphoid compartment. 
(A) T cell gating strategy. (B) Percentages of live TCRβ+ total T cells. (C) Percentages of live TCRβ+ CD4+ T cells 
(left panel) and of CD4+ CD44+ CD62L- activated T cells (right panel). (D) Percentages of live TCRβ+ CD8+ T cells 
(left panel) and of CD8+ CD44+ CD62L- activated T cells (right panel). Data representation, number of mice, and 
statistics are as in Figure 5. 
 
 
 
 
 
 
 
 
 25 
2.3 SYSTEMIC LUPUS ERYTHEMATOSUS IS INDEPENDENT OF ELANE IN THE 
MRL.FASLPR MURINE MODEL 
To assess the role of Elane-deficiency in SLE, we utilized the Elane-Cre mouse. Here, a 
modified bacteriophage P1-derived Cre recombinase gene was incorporated at the ATG start 
codon of the Elane gene generating a knockin that inactivates the Elane locus (130). We fully 
backcrossed the Elane-/- allele onto crossing MRL.Faslpr background for 9 generations. 
Heterozygous mice were then intercrossed to produce an experimental cohort. SLE pathology 
was analyzed at 17 weeks of age.  
2.3.1 Elane deficiency had no effect on nephritis or dermatitis 
No differences in urine protein were detected across Elane genotype in both male and female 
cohorts (Figure 8A). Elane deficiency had no impact on dermatitis (Figure 8B). No statistically 
significant differences in glomerulonephritis or interstitial nephritis were detected among the 
different Elane genotypes in either cohort (Figure 8C and D). Similarly, Elane genotype did not 
alter splenomegaly or lymphadenopathy (Figure 8E and F).  
2.3.2 Elane genotype has a minor impact on loss of tolerance or anti-self responses 
The autoantibody response was not altered in the context of Elane deficiency. We did not detect 
any change in anti-RNA antibody (Figure 9A), anti-Sm antibody (Figure 9B), anti-nucleosome 
antibody (Figure 9C), and rheumatoid factor (Figure 9D) titers among the groups. Concordant 
with these data, there were no statistically significant differences in total kappa Ig AFC ELISpots 
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(Figure 10A). Wild-type female mice had a higher number of IgG1 AFCs compared to their 
Elane-deficient MRL.Faslpr counterparts (Figure 10B). This finding is unlikely to be biologically 
significant, as these data were not mirrored across gender. Similar AFC ELISpot results were 
obtained for the IgG2a and IgM isotypes (Figure 10C & D). Furthermore, Elane-genotype did 
not affect the percentages of CD19+ B cells (Figure 10E) or CD19low-int CD44+ CD138+ 
intracellular κhigh AFCs (Figure 10F).  
2.3.3 Elane deficiency did not substantially change the myeloid compartment 
Elane genotype had only a minor impact on the myeloid compartment in MRL.Faslpr mice. The 
percentages of CD11b+Ly6G+ (Figure 11A) BM neutrophils and CD11b+F4/80+Gr1low-int BM 
macrophages (Figure 11B) were not statistically different among the groups. Additionally, no 
changes in CD11b+Ly6G+ (Figure 11C) splenic neutrophils or CD11b+F4/80+Gr1low-int (Figure 
11D) splenic macrophages were identified across Elane genotype. Female wild-type mice had a 
greater percentage of splenic cDCs compared to the Elane-/- group (Figure 11E). No differences 
in the percentages of CD19-BST2+ SiglecH+ pDCs (Figure 9F) were identified among Elane 
genotypes. 
2.3.4 Elane deficiency had a modest impact on the lymphoid compartment 
Elane deficiency did not substantially impact the lymphoid compartment. All genotypes 
exhibited indistinguishable total percentages of TCRβ+ T cells (Figure 12A). The percentages of 
CD4+ T cells were elevated in female wild-type mice (Figure 12B) while CD4+CD44+CD62L- 
activated T cells were elevated in male Elane-/- mice (Figure 12B). The percentages of CD8+ T 
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cells and CD8+CD44+CD62L- activated T cells were similar amongst wild-type and Elane-
deficient mice (Figure 12C). 
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Figure 8. Elane genotype did not impact lupus nephritis, dermatitis, or lymphadenopathy/splenomegaly. 
(A) Proteinuria. (B) Dermatitis scores. (C) Glomerulonephritis scores. (D) Interstitial nephritis scores. (E) Spleen 
weight. (F) Axillary lymph node weights. Scores and weights are represented as a function of Elane-genotype and 
gender at 17 weeks of age. Bars represent the median and each dot represents and individual mouse. A two-tailed 
Mann-Whitney U test was performed to determine statistical significance within each gender (* indicates p≤0.05, ** 
p≤0.01, *** p≤0.001, and **** p≤0.0001; n=9 to 20 mice per group). 
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Figure 9. Elane genotype does not significantly alter the anti-self response. 
(A-D) Serum anti-RNA (A), anti-Sm (B), anti-nucleosome (C), and rheumatoid factor (D) antibody titers at 17 
weeks of age. The dotted line denotes the upper limit of quantitation. Data representation, number of mice, and 
statistics are as in Figure 8.  
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Figure 10. Elane deficiency did not change the AFC compartment. 
(A-D) Numbers of Igκ (A), IgG1 (B), IgG2a (C), and IgM (D) antibody forming cells (AFCs) per spleen as 
determined by ELISpot. (E) Percentages of live CD19+ total B cells. (F) Percentages of live cells that are TCRβ− 
CD44+ CD138+ intracellular κ+ AFCs. Data representation, number of mice, and statistics are as in Figure 8. In panel 
E and F, bar graphs are represented as the mean ± SEM and a two-tailed Welch’s T test was performed to determine 
statistical significance within each gender (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=9 to 
20 mice per group).   
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Figure 11. Elane genotype did not substantially affect the myeloid and DC compartments. 
(A) Percentages of live bone marrow (BM) CD11b+ Ly6G+ neutrophils. (B) Percentages of BM CD11b+ GR1low-int 
F4/80+ macrophages.  (C) Percentages of live CD11b+ Ly6G+ neutrophils in the spleen. (D) Percentages of splenic 
CD11b+ GR1low-int F4/80+ macrophages. (E) Percentages of live CD19- MHCII+ CD11c+ conventional dendritic cells 
and (F) CD19- BST2+ CD11c+ plasmacytoid dendritic cells. Bar graphs are represented as the mean ± SEM and two-
tailed Welch’s T test was performed to determine statistical significance within each gender (* indicates p≤0.05, ** 
p≤0.01, *** p≤0.001, and **** p≤0.0001; n=9 to 20 mice per group).   
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Figure 12. Elane deficiency had little impact on the lymphoid compartment. 
(A) Percentages of live TCRβ+ total T cells. (B) Percentages of live TCRβ+ CD4+ T cells (left panel) and of CD4+ 
CD44+ CD62L- activated T cells (right panel). (C) Percentages of live TCRβ+ CD8+ T cells (left panel) and of CD8+ 
CD44+ CD62L- activated T cells (right panel). Data representation, number of mice, and statistics are as in Figure 
11. 
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2.4 DISCUSSION 
Collectively, the genetic studies presented here fail to support the hypothesis that PADI4 or 
ELANE and by extension NET generation, alters immune system composition or pathology in 
SLE. We initially approached these studies by generating F2 cohorts of Padi4-deficient mice on 
the MRL.Faslpr background by crossing the Pad4-/- C57BL/6 and Padi4+/+ MRL.Faslpr strains 
followed by intercrossing F1 progeny. Resulting lpr homozygotes have 50% of the SLE loci and 
typically develop clinical features of SLE associated with lymphoproliferation by 16–24 weeks 
of age. The F2 approach is an operationally reliable genetic screen to identify potential mediators 
of disease pathogenesis, an approach successfully used by our group and others (4, 31, 75, 131, 
132). Execution of two independent genetic experiments using a mixed background F2 and a 
fully backcrossed Padi4-deficient MRL.Faslpr cohort, with both yielding the same results, 
strengthens these conclusions. 
 To independently confirm our genetic results that Padi4-deficiency did not affect 
nephritis in the MRL.Faslpr lupus model, we collaborated with Tanya Mayadas’ group to test the 
Pan-PAD inhibitor, N-R-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide (Cl-Amidine), 
in a murine model of proliferative anti-glomerular basement membrane (GBM) nephritis induced 
by the injection of rabbit anti-GBM containing sera in mice expressing FcγRIIA selectively on 
neutrophils (119). In this model, antibodies directed to the glomerular basement membrane 
trigger an inflammatory reaction that results in severe damage of the kidney that depends on 
neutrophil FcγRIIA. Daily treatment of mice subjected to the anti-GBM nephritis model with Cl-
Amidine did not inhibit the development of kidney damage, as measured by proteinuria and 
histological signs of inflammation (133). Additionally, analysis of leukocyte recruitment to the 
kidneys showed no reduction in Cl-Amidine versus vehicle treated animals (133).  
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Furthermore, FcγRs play a key role in autoimmune mediated organ damage (134, 135). 
To evaluate the effects of PAD inhibition specifically in the development of organ damage 
relevant to human disease, we partnered with the Mayadas laboratory to employ a passive human 
SLE-serum transfer model of nephritis (136). In this model, mice that transgenically express the 
human FcγRIIA selectively on neutrophils and additionally lack the β2 integrin Mac-1 are 
susceptible to developing nephritis upon the intravenous injection of serum from patients with 
SLE (136). At day 10 after sera injection such mice develop proteinuria that correlates with 
neutrophil infiltration into the kidneys. Histological signs of disease including hypercellularity, 
endocapillary proliferation, and crescent formation are evident at day 14. Daily i.p. treatment 
with Cl-Amidine did not reduce albuminuria or histological signs of kidney damage (133). 
Moreover, we did not observe a reduction in neutrophil or macrophage infiltration compared 
with vehicle treated animals (133).   
Corroborating our studies, Padi4 deficiency does not reduce renal disease or the anti-self 
response in the pristane induced model of SLE (PIL) (137). In fact, Padi4-deficient mice 
subjected to PIL developed more severe proteinuria, increased auto-antibody titers, and pro-
inflammatory cytokine production (137). Similarly, Mpo-deficient mice had more severe 
nephritis in the PIL model (138). Intriguingly, genetic ablation of neutrophils in the PIL model 
did not protect against lupus renal disease, and in fact, there are elevated levels of autoantibodies 
observed in this setting (137). While neutrophils were conventionally thought to play a pro-
inflammatory role in autoimmunity, these data suggest an important regulatory role in SLE. We 
and others targeted four major mechanisms implicated in NET formation in multiple SLE and 
proliferative nephritis models. Taken together, these data strongly argue against the hypothesis 
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that NETs are a major source of autoantigen in SLE and a dominant mediator of end organ 
damage. 
Our Padi4-deficient MRL.Faslpr results are discordant with previously reported PADI 
inhibitor studies utilizing Cl-Amidine and BB-Cl-Amidine in both MRL.Faslpr (69) and New 
Zealand Mixed 2328 (NZM) (70) models. One possible explanation is that the (halo) 
acetamidine-based PAD inhibitors could affect other PADI family members (69, 139). As with 
most inhibitors administered at high dose over long periods in vivo, it is difficult to exclude off-
target effects even beyond the related PAD enzymes. Despite the fact that only PADI4 has been 
implicated in NET formation and its deletion demonstrates a non-redundant effect on NET 
assays (65, 66, 106), it can be speculated that the ability of (halo) acetamidine-based PAD 
inhibitors to block related enzymes could account for the differences between specific genetic 
deletion of Padi4 and prior inhibitor studies. However, we believe this explanation to be less 
likely as Cl-Amidine pan-PAD specificity would not account for the lack of phenotype identified 
in the inhibitor studies using inducible models of glomerulonephritis reported here.  
Moreover, our inhibitor data in IC-FcγR dependent nephritis models conflict with a 
recent report by Ander’s group demonstrating that Cl-Amidine reduces severity of proliferative 
nephritis in the anti-GBM model (140). The discrepancies with published data are unlikely due 
to differences in treatment protocols or pharmacokinetic issues. As our studies were conducted in 
multiple models and in various mouse strains housed at three different animal facilities, it is 
unlikely that the lack of observed phenotype is due to differences in the microbiome. 
Furthermore, disease in MRL.Faslpr germ-free mice was not grossly altered (141), again 
suggesting that microbiome is not a major factor in the model.  
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Although Cl-Amidine has a short half-life, it is an irreversible inhibitor, allowing for 
prolonged inhibition of NET generation (142). We confirmed Cl-Amidine efficacy in vivo by 
visualizing NETs in the cremaster muscle following the reverse passive arthus (RPA) reaction by 
intravital microscopy. Immune complexes formed upon induction of the RPA in the cremaster 
muscle of the mouse induced NET formation that required neutrophil FcγRs (96). Cl-Amidine 
continued to significantly reduce NET formation to levels observed in Padi4-deficient mice 20 
hours post administration, reinforcing the conclusion that the protocol of Cl-Amidine treatment 
in our nephritis model was effective in reducing PAD activity (133). Since PAD inhibition 
reduces NET formation to that observed in Padi4-deficient mice, it is unlikely that other PAD 
family members are serving in a compensatory capacity to generate NETs.  
Recent evidence suggests that B cell tolerance to deaminated histones may be different 
between mice and humans (143). Patients with systemic autoimmune diseases including 
rheumatoid arthritis, SLE, and Felty’s syndrome can develop antibodies towards citrullinated 
protein antigens (101-103). In contrast, sera from SLE prone mouse strains including NZB/W, 
B6.Sle1, B6.Sle1.Sle3, and NZM2410 preferentially bind non-deiminated histones (143). 
Interestingly, splenocytes from 25-week old autoimmune NZB/W mice proliferate in response to 
citrullinated and non-citrullinated histones without bias (143). These data suggest that 
autoimmune mice may maintain strong tolerance mechanisms to prevent the development of 
autoantibodies to deiminated histones, a finding inconsistent with the efficacy of pan-PAD 
inhibitors in the NZM and MRL models of SLE. Importantly, our findings and those presented 
by Dwivedi and colleagues highlight that systemic autoimmunity can occur in the absence of loss 
of tolerance to citrullinated antigens produced by NETs or by other mechanisms.  
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Neutrophils exposed to lupus serum and SLE associated stimuli have a greater propensity 
to generate NETs (68, 70, 136). However, our data disassociate the correlation between NET 
formation in lupus patients and mice from disease pathogenesis. Close analysis of published data 
in clinical settings is consistent with this dissociation. For instance, while NET degradation is 
impaired in some SLE patients, in fact 59-88% of SLE patients actually do degrade NETs 
adequately (71, 72, 144). Additionally, no statistical correlation was found between autoantibody 
titers, therapy, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and ex vivo 
NET production at baseline (67). Taken together, the data reported here coupled with our 
previously published results in NADPH oxidase-deficient lupus prone mice, should lead the field 
to revisit and question whether NETs per se are critical drivers of autoimmunity or end-organ 
damage. 
ELANE, the second most abundant protein in NETs, is critical for NET formation by 
modulating F-actin dynamics and degrading histones important for chromatin decondensation 
(111). In addition to its active role in NET formation, ELANE decorates NET structures and is 
proteolytically active in this setting (145). Aggregated NETs can degrade cytokines in an 
ELANE- dependent manner as treatment of these structures with multiple elastase inhibitors 
prevented the degradation of cytokines and chemokines (85). NADPH oxidase-deficient mice 
subjected to a monosodium urate crystal induced model of chronic neutrophilic inflammation, 
similar to gout, developed more severe arthritis (85). This phenotype is attributed to the inability 
of NADPH oxidase-deficient mice to generate aggregated NETs. Moreover, the adoptive transfer 
of aggregated NETs into these animals reduced disease severity (85). These data coupled with 
the exacerbated disease observed in Cybb-deficient SLE prone mice and Padi4-deficient mice 
subjected to the PIL model suggests a homeostatic function for NETs in autoimmunity. It is 
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conceivable that ELANE protease activity could alter self-antigen impacting its immunogenicity. 
As Elane deficiency did not impact the anti-self response nor clinical parameters of SLE in the 
MRL.Faslpr model, this is less likely to be a significant mechanism of loss of tolerance in 
autoimmunity.  
While many groups implicate ELANE as a critical mediator of NET formation, several 
reports suggest that NETs can occur in the absence of ELANE. SLE related stimuli, such as 
immune complexes, can induce ELANE-independent NET formation (96). Since Padi4 
deficiency and pharmacological inhibition reduces NET formation in this setting and PADI4 
pharmacological inhibition or genetic deletion does not impact SLE pathogenesis, we do not 
believe ELANE-independent NETs to contribute to autoimmunity. Neutrophils from Elane-
deficient mice or wild-type neutrophils pretreated with ELANE inhibitors are reported to form 
NETs in response to canonical NET inducing stimuli, such as PMA and calcium ionophores 
(146, 147). In contrast to genetic deletion of Padi4, Elane-deficient mice form NETs in an 
experimental model of deep venous thrombosis (DVT) and Elane deficiency does not protect 
mice from DVT in this model (146). It is conceivable that other serine proteases such as 
Cathepsin G and Proteinase 3 serve redundant roles in mouse and humans, accounting for these 
differential findings in the literature. The role of ELANE in NET formation remains 
controversial and must be reconciled. While we cannot rule out that the lack of phenotype 
observed in our study is due to compensation from other serine proteases, our data demonstrate 
that ELANE and by extension, ELANE-dependent NET formation does not impact SLE 
pathology.  
NETs are evolutionarily conserved, suggesting a homeostatic function (148). Consistent 
with the modified view favored by our results, other recent publications suggest that NETs are 
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not always proinflammatory and may even be immunomodulatory. Clearance of NET-like 
structures is an immunologically silent process and does not lead to pro-inflammatory cytokine 
production (149). Mice immunized with NETs do not break tolerance and show trace urinary 
protein levels up to 14 weeks post immunization (150). Moreover, aggregated NETs can 
ameliorate inflammation by inducing proteolytic cleavage of inflammatory mediators (85).  
NETs thus may have evolved, in part, to protect us from rather than promote autoimmunity 
(151). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 40 
2.5 MATERIALS AND METHODS 
Mice. Padi4-deficient C57BL/6 mice were a kind gift from Dr. Yanming Wang (Center for 
Eukaryotic Gene Regulation, Department of Biochemistry and Molecular Biology, Pennsylvania 
State University, University Park, PA). Elane-Cre C57BL/6 mice were generously provided by 
Jürgen Roes (Department of Medicine, University College London, London, United Kingdom). 
Fully backcrossed mice were obtained by crossing the Padi4-/- or the ElaneCre/wt allele onto the 
MRL.Faslpr (The Jackson Laboratory catalogue # 000485) background for at least 9 generations. 
Heterozygous mice were then intercrossed to produce an experimental cohort. SLE pathology 
was analyzed at 16 weeks for F2 and 17 weeks for backcrossed cohorts. All mice were housed 
under specific-pathogen-free (SPF) conditions. Animal studies were approved by the University 
of Pittsburgh Institutional Animal Care Use Committee 
 
Evaluation of SLE pathology. MRL.Faslpr SLE cohorts were analyzed as previously described 
(75, 80). For skin disease, mice were scored based on the extent of lesions on the dorsum of the 
neck and back. Macroscopic surface area was scored from 0 to 5 for an affected area up to 9.1 
cm2, with up to 1 additional point for the presence of ear (1/4 point each) and muzzle (1/2 point) 
dermatitis (152).  
Proteinuria was screened using Albustix (Siemens). Plasma was obtained by cardiac 
puncture. Kidneys were removed, bisected, formalin-fixed, paraffin embedded, and H&E 
stained. Kidneys were scored for glomerulonephritis on a scale of 1-6 and interstitial nephritis on 
a scale of 1-4 in a blinded manner by a clinical pathologist (75).  
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Flow Cytometry. Flow cytometry was performed as previously described (75). In brief, spleens 
and bone marrow were homogenized and red blood cells were lysed using Ammonium-Chloride-
Potassium buffer (prepared in house). Cells were resuspended in Phosphate Buffered Saline 
(PBS) with 3% calf serum and the FcR-blocking antibody 2.4G2. Live/dead discrimination was 
performed using fixable viability stain 510 (BD) or ethidium monoazide bromide (Invitrogen). 
Surface and intracellular staining antibodies are listed below. Cells were fixed in 1% 
paraformaldehyde or Cytofix/Cytoperm (BD) where appropriate. Data were obtained using a 
LSRII (BD) with FACS DIVA software and analyzed using FlowJo.  
 
Antibodies used for FACS staining. Antibodies used for FACS surface and intracellular staining 
were as follows: IA/E-PE (Biolegend, M5/114.15.2), IA/E-APC/Cy7 (Biolegend, M5/114.15.2), 
Bst-2-biotin (in-house conjugated, 927), CD11c-PE/Cy7 (BD Pharmigen, HL3), CD11c-AI488 
(eBioscience, N418), CD45R-APC/Cy7 (BD Pharmigen, RA3-6B2), SiglecH-Al647 
(eBioscience, eBio440c), Ly6G-Al488 (in-house conjugated, 1A8), Ly6G-biotin (in-house 
conjugated, 1A8), Gr1-PE/Cy7 (Biolegend, RB6-8C5), Gr1-PE (Biolegend, RB6-8C5), CD11b-
APC/Cy7 (Biolegend, M1/70), CD11b-PE (Biolegend, M1/70), F4/80-Al647 (in-house 
conjugated, BM8), F4/80-APC (Biolegend, BM8), CD44-Al488 (in-house conjugated, 1M7), 
CD44-APC-Cy7 (Biolegend, 1M7), TcRβ-APC/Cy7, (Biolegend, H57-597), TCRβ-PE/Cy7,  
(Biolegend, H57-597), TCRβ-PerCP/Cy5.5  (Biolegend, H57-597), CD62L-PE/Cy7 (Biolegend, 
Mel-14), CD8-Al647 (in-house conjugated, TIB 105), CD4-PE (in-house conjugated, GK1.5), 
CD138-PE (BD Pharmigen, 281-2), CD19-Pacblue (in-house conjugated, 1D3.2), CD19-AI647 
(in-house conjugated, 1D3.2), kappa-AI488 (in-house conjugated, 187.1), kappa-Pacblue (in-
house conjugated, 187.1), and GFP-FITC (Rockland, polyclonal). 
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ELISpot assays. AFC producing κ light chain antibodies, IgG1, IgG2a, or IgM were detected by 
ELISpot as previously described (11). In brief, 96-well Immulon 4 HBX plates were coated 
overnight at 4°C with 5 mg/ml polyclonal goat-anti mouse κ (Southern Biotech; 1050-01). 
Nonspecific binding was blocked with 1% bovine serum albumin in PBS and samples were 
incubated at 37°C. Alkaline phosphatase-conjugated secondary antibodies (Southern Biotech; 
Igκ [1050-04], IgG1 [1070-04], IgG2a [1080-04], or IgM [1020-04]) were detected with bromo-
4-chloro-3-indolyl phosphate substrate (Southern Biotech).  
 
ELISAs. Anti-Sm, anti-nucleosome, anti-RNA, rheumatoid factor, total IgM, and IgG ELISAs 
were performed as previously described (2, 4, 75, 153, 154).  Specific antibodies were detected 
with alkaline phosphatase-conjugated goat anti-mouse IgG (Southern Biotech [1030-04]). The 
monoclonal antibodies Y2, BWR4, 400tµ23, PL4-2 or PL2-3 (in-house) were used as standards 
for the anti-Sm, anti-RNA, rheumatoid factor, and anti-nucleosome measurements respectively.  
 
Statistics. Statistical analysis was performed using Prism 7.0 (Graphpad). A Kruskal-Wallis test 
with post-hoc Dunn’s test, two-tailed Mann-Whitney U test, two-tailed Welch’s t test, and a one-
way ANOVA with post hoc Holm-Sidak test were performed where indicated and appropriate. A 
p value <0.05 was considered statistically significant. 
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3.0  INVESTIGATING THE CELL SPECIFIC ROLE OF CYBB IN THE 
PATHOGENESIS OF SLE 
3.1 INTRODUCTION 
The NADPH oxidase complex is at the nexus of numerous innate and adaptive immune signaling 
cascades, situated to be a central pleiotropic mediator of the host response to pathogens and to 
self. We and others have implicated the NADPH oxidase complex as a central regulator of 
autoimmunity in mice and humans (1–8). 
3.1.1 The NADPH oxidase complex: structure, regulation, and function 
The NOX NADPH oxidases are a family of transmembrane enzymes that oxidize intracellular 
NADPH, facilitating electron transport across the membrane and subsequent reduction of 
molecular oxygen into superoxide. There are seven NOX family members, including NOX1-5 
and DUOX1-2, each with differential tissue distribution (155). NOX2 was historically referred to 
as the “phagocyte” NADPH oxidase as it is primarily expressed in phagocytic cells, such as, 
neutrophils and macrophages (155, 156). Flavocytochrome b558, located in intracellular 
vesicles, is the catalytic core of the phagocyte NADPH oxidase complex. Cytochrome b-245 β 
polypeptide (CYBB; NOX2; GP91) and cytochrome b-245 alpha (CYBA; p22phox) constitute 
flavocytochrome b558 (Figure 13).  The catalytic core is regulated by the cytosolic subunits 
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p67phox (NCF2), p47phox (NCF1), and p40phox (NCF4). NADPH complex activity is tightly 
regulated under steady state conditions (155, 156) (Figure 13). In the resting state, regulatory 
subunits of the NADPH oxidase complex, P67phox, P40phox, and p47phox, exist as a trimer while 
RAC is associated with its inhibitor GDI (155-157) (Figure 13). Little CYBB/CYBA 
heterodimer is located in the plasma membrane (155, 156). The negative regulator of reactive 
oxygen species (NRROS) can associate with the emerging CYBB monomer enabling its 
degradation by the endoplasmic reticulum associated degradation pathway (158). A variety of 
different stimuli can prime the NADPH oxidase complex including adhesion, engagement of 
pattern recognition receptors (PRRs), and proinflammatory cytokines (156, 159). Upon priming, 
the cytosolic trimer relocates to the flavocytochrome b558 complex in the plasma membrane 
(159). Phosphorylation of p47phox enables its translocation to the plasma membrane where it can 
interact with the catalytic core (159) (Figure 13). The primed NADPH oxidase complex can be 
fully activated by similar signals to generate an oxidative burst (155, 156, 159).  
In response to microorganisms and inflammatory stimuli, professional phagocytes 
undergo an NADPH oxidase complex-dependent oxidative burst, producing reactive oxygen 
(ROS) species requisite for microbial killing (155, 156, 159). Mice and humans without the 
functional NADPH oxidase complex are more susceptible to bacterial and fungal infections such 
as Staphylococcus aureus and Aspergillus fumigatus (120, 160). More recently, 
immunomodulatory roles for the NADPH oxidase complex within the myeloid compartment and 
in the lymphocytes have been characterized, as detailed below. The immune modulatory 
functions of the NADPH oxidase complex could represent an important checkpoint in the 
initiation and progression of the anti-self response.    
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3.1.2 The regulatory role of NADPH oxidase in the myeloid compartment 
The recognition and removal of dead cells and associated debris is a critical step towards the 
resolution of inflammation and important to prevent immune recognition of self. The NADPH 
oxidase complex is important for the clearance of dead cells by macrophages. Upon apoptotic 
cell death, phosphatidylserine (PS) is transferred from the inner leaflet to the outer membrane 
where it can initiate the ingestion of the dead cell (55). Both the externalization of PS and 
subsequent uptake of the dying cell by macrophages is dependent on NADPH oxidase generated 
ROS. It has also been shown that NADPH oxidase is required for the oxidative modification of 
PS to lysophosphatidylserine which can be recognized by the G-protein-coupled receptor G2A 
on macrophages, facilitating uptake of dying cells (84, 161, 162). Engagement of the G2A 
receptor by lyso-PS induces prostaglandin E2 (PGE2) (163). PGE2 engages the prostaglandin E2 
(EP2) receptor on the activated macrophages in an autocrine and paracrine manner to induce 
adenylate cyclase and protein kinase A (163). This cascade activates Rac1 which is required for 
the engulfment of dying cells. NADPH oxidase-deficient macrophages from humans and mice 
exhibit an impaired ability remove dead cells (163). Interestingly, IFNγ priming can restore 
ability of NADPH oxidase deficient macrophages to engulf dead cells via a TNFα and Nitric 
oxide-dependent mechanism (86). More recently non-conical autophagy or LAP has been 
implicated in the degradation of dead cell debris by macrophages (164). LAP occurs when 
particles that induce phagocytosis concomitantly engage cell surface receptors and recruitment of 
autophagy machinery, facilitating phagosome maturation and the degradation of the engulfed 
content (89, 164). Reports suggest that CYBB is requisite for LAP and that LAP-deficient mice 
develop spontaneous autoimmunity (89, 90). The role of CYBB and LAP will be detailed in 
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chapter 4. Taken together, these studies highlight an important role for NADPH oxidase in dead 
cell clearance. Dysfunctional clearance of dead cell cells and resulting debris could provide a 
source of autoantigen fostering the development of systemic autoimmunity. 
NADPH oxidase-dependent ROS are critical for the formation of classical NETs (63, 64). 
While the putative role of NETs was initially thought to be proinflammatory in the context of 
autoimmunity, recent evidence suggests that this is not the case, and in fact, NETs may be 
immunomodulatory (75, 133, 137). In response to monosodium urate crystals, a murine model 
for gout, NADPH oxidase-dependent NETs can form aggregated structures that degrade 
proinflammatory cytokines (85). Padi4-deficient mice, which have impaired NET formation, 
develop exacerbated manifestations of SLE when subjected to pristane-induced lupus (137). It is 
thus plausible that one mechanism by which NADPH oxidase exerts its protective effects is 
through the formation of classical NETs, which in turn are protective rather than pathogenic. The 
role of NETs, NADPH oxidase, and SLE are further discussed in chapter 2.  
3.1.3 NADPH oxidase has a duel stimulatory and inhibitory role in B cells 
While the NADPH oxidase complex is predominantly expressed in phagocytes and best 
described in the myeloid compartment, it is also expressed and functional in lymphocytes. 
CYBB is postulated to be the primary source of H2O2 in B cells and is important for efficient 
activation and differentiation (165). In one study, H2O2 is transported by aquaporin 8 across the 
membrane to enhance B cell receptor (BCR) signaling (165). BCR signaling induces early 
production of ROS that is dependent on CYBB but later ROS production is a product of 
mitochondrial respiration (166). While Cybb-deficient B cells did not generate detectable early 
ROS upon B cell stimulation, BCR signaling and BCR-induced activation and proliferation 
 47 
remained intact pointing to a critical role for mitochondrial ROS in B cell function (166). B cells 
are reported to have a high phagocytic capacity and can generate NADPH oxidase-dependent 
ROS (167). Reciprocally, NADPH oxidase deficient B cells demonstrate reduced bacterial 
killing capacity (167). Contrary to these reports, other groups suggest that B cell CYBB 
generated ROS negatively regulates BCR induced cell cycle entry, proliferation and T cell 
independent antibody responses (88). Patients with chronic granulomatous disease (CGD), 
characterized by loss of function mutations in NADPH oxidase subunits, have an impaired B cell 
memory compartment with reduced numbers of CD19+CD27+ and resting CD19+ CD27+ CD21+ 
memory B cells (168). Concordantly, these patients have lower measles-specific antibody titers 
and antibody secreting cell numbers (168). Similar to murine studies, B cells isolated from CGD 
patients have a reduced capacity to respond to BCR and TLR9 stimuli (169). Taken together, 
these studies emphasize that the function of NADPH oxidase in B cells requires further 
exploration. 
3.1.4 Immunomodulatory functions of NADPH oxidase in T cells 
The phagocyte NADPH oxidase complex is expressed and functional in T cells but its role in 
immune function remains enigmatic. T cell receptor (TCR) stimulation induces sustained H2O2 
production requiring preformed FAS and FAS ligand to induce NADPH oxidase ROS (87). 
NADPH oxidase-deficient T cells intrinsically skew towards the T helper (Th)1, Th2, and Th17 
lineages (82, 170, 171). Concordantly, adoptive transfer of Cybb-deficient CD4 T cells into a 
RAG-deficient host increases arthritis severity, suggesting intrinsic T cell CYBB-dependent 
ROS production regulates T cell responses (82). More recently, it has been shown that CD8+ T 
regulatory (Tregs) cell suppression requires CYBB dependent ROS production (172). 
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Intriguingly, CD8+ Tregs suppressed CD4+ T cell function by transferring CYBB to CD4+ T cells 
via exosomes (172). Surprisingly, CD8+ Tregs from older human subjects are CYBB-deficient, a 
finding that also extends to patients with Giant Cell Vasculitis, an autoimmune disease 
characterized by inflammation of medium and large blood vessels (172).   
CYBB can regulate T cell responses by extrinsic mechanisms. Indoleamine 2,3-
dioxygenase (IDO), suppresses T cell responses by degradation of tryptophan (173, 174). Pro-
inflammatory stimuli, such as IFNγ, can induce IDO expression in dendritic cells and phagocytes 
(173-175). ROS are an important mediator for the oxidative cleavage of tryptophan. Cybb-
deficient mice exhibit a blockade in tryptophan metabolism and in turn detrimental 
immunopathology in the setting of Aspergillus fumigatus infection mediated by γδ T cells, 
increased IL-17 production, and a reduction in Tregs (176). However, diverging from this 
finding in mice, CGD patients do not display a defect in IDO activity (177, 178). These studies 
suggest a fundamental regulatory role for NADPH oxidase in T cell function, representing a 
potential mechanism to restrain T cell mediated autoimmunity.  
3.1.5 NADPH oxidase in SLE 
A connection between X-linked CGD and systemic autoimmunity was first reported over 60 
years ago (179). Male patients with X-linked CGD, characterized by loss of function mutations 
in CYBB, are at greater risk of developing SLE (120). This observation extends to carrier 
mothers of affected males, indicating that heterozygous dosing of the CYBB allele is sufficient to 
drive SLE susceptibility (121, 122). More recently, loss of function polymorphisms in NCF1 and 
NCF2 are reported to confer increased SLE risk across multiple ethnic groups (123-125). Mouse 
models of CGD, in which critical components of the NADPH oxidase complex have been 
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genetically deleted, recapitulate increased autoimmunity susceptibility observed in human 
patients. NADPH oxidase-deficient C57BL/6 non-autoimmune mice develop a spontaneous 
lupus-like disease (89, 180). Clinical and immunological manifestations of SLE were 
exacerbated in Cybb-deficient MRL.Faslpr mice (75). Reinforcing these findings, Ncf2 deficiency 
in the NZM.2328 lupus prone mouse strain worsened renal manifestations of SLE and the anti-
self response (76). Mice harboring the Ncf1m1j loss of function mutation developed aggravated 
arthritis when subjected to the collagen induced arthritis model (181). Similarly, Ncf1m1j mice 
develop more severe SLE when triggered by intraperitoneal injection of pristane (137). 
Strikingly NADPH oxidase agonists reduced pristane-induced SLE kidney disease, autoantibody 
titers, and the production of pro-inflammatory cytokines (137). Collectively, these studies show 
that the phagocyte NADPH complex is critical for the regulation of autoimmune pathology in 
mice and humans.   
 While, NADPH oxidase-dependent ROS is protective in the setting of autoimmunity, the 
mechanism(s) that constrain pathologic inflammation in vivo are unknown. Here, we aim to 
establish in which cell type does Cybb deficiency drive systemic autoimmunity by employing in 
vivo chimera and conditional knockout approaches to delete Cybb on specific cell subsets in the 
MRL.Faslpr SLE model.  
3.2 ASSESSMENT OF HEMATOPOIETIC CYBB ON THE PATHOGENESIS OF 
SLE 
While CYBB is predominantly expressed in the myeloid compartment, in recent years it has 
become apparent that it is also expressed in lymphocytes and the stroma, including the 
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endothelium, fibroblasts, muscle, and hepatocytes (155, 156). To determine whether CYBB in 
the hematopoietic compartment is the primary driver of the exacerbated manifestations of 
autoimmunity that we and others observe in global Cybb-deficient mice, we generated reciprocal 
bone marrow chimeras. Here, Cybb-sufficient or -deficient MRL.Faslpr SLE prone mice were 
irradiated at 6-7 weeks of age and reconstituted with either Cybb-sufficient or Cybb-deficient 
MRL.Faslpr bone marrow. SLE pathology was assessed in chimeric mice 16 weeks post 
irradiation unless otherwise indicated. 
3.2.1 Hematopoietic Cybb deficiency decreased survival and exacerbated kidney disease 
in the MRL.Faslpr SLE mouse model 
Hematopoietic Cybb deficiency recapitulated exacerbated clinical manifestations of SLE 
observed in global Cybb-/- MRL.Faslpr mice. Strikingly, hematopoietic Cybb deficiency 
decreased survival of MRL.Faslpr females (Figure 14A). Urine protein was elevated in mice 
receiving Cybb-/- bone marrow (Figure 14B). Concordantly, Cybb-deficient bone marrow 
reconstitution worsened glomerular and interstitial nephritis (Figure 14C and D). Spleen weight 
was increased in MRL.Faslpr mice with a hematopoietic Cybb defect (Figure 15A). However, no 
differences in lymphadenopathy were observed across groups (Figure 15B).  
3.2.2 Hematopoietic Cybb deficiency altered the anti-self response in MRL.Faslpr mice 
We have previously shown that Cybb-deficient and the heterozygous female MRL.Faslpr mice 
were more likely to make high-titers of antibodies to RNA and to the ribonucleoprotein SM. 
Here, anti-RNA titers were elevated in male mice with a hematopoietic Cybb defect (Figure 
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16A). However, this phenotype was not observed in female MRL.Faslpr mice. It is possible that 
as female SLE prone mice develop disease with faster kinetics compared to their male 
counterparts, we missed the window of difference. Hematopoietic Cybb deficiency did not alter 
anti-Sm titers (Figure 16B). Intriguingly, anti-nucleosome titers were reduced in SLE-prone mice 
with a hematopoietic Cybb defect (Figure 16C), a finding not observed in the setting of global 
Cybb deficiency. Rheumatoid factor titers were reduced in female mice reconstituted with Cybb-
deficient bone marrow (Figure 16D). As this finding was not seen in male mice, its biological 
significance is unclear. 
3.2.3 The B cell and AFC compartment were not altered in SLE prone mice with a 
hematopoietic Cybb defect 
AFCs were expanded in the absence of global Cybb in the MRL.Faslpr. This finding was not 
recapitulated in MRL.Faslpr with a hematopoietic Cybb defect. There were no statistically 
significant differences in total kappa Ig AFC ELISpots (Figure 17A). Similar AFC ELISpot 
results were obtained for the IgG1, IgG2a, and IgM isotypes (Figure 17B-D). Furthermore, 
hematopoietic Cybb deficiency did not affect the percentage of CD19+ B cells (Figure 4E) or 
CD19low-int CD44+ CD138+ intracellular κhigh AFCs (Figure 4F).  
3.2.4 Hematopoietic Cybb deficiency was sufficient to expand the myeloid compartment 
MRL.Faslpr mice 
We previously reported that Cybb-/- MRL.Faslpr mice had an expanded myeloid compartment, 
characterized by increased percentages of splenic neutrophils and macrophages. Female mice 
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with a hematopoietic Cybb defect had an increased percentage of bone marrow neutrophils 
(Figure 18A) but not macrophages (Figure 18B). The percentages of splenic neutrophils and 
macrophages were increased in both female and male SLE prone recipients reconstituted with 
Cybb-/-  bone marrow. (Figure 18C and D). No differences in the percentages of CD19-
CD11c+MHCII+ cDCs (Figure 18E) and CD19-BST2+ SiglecH+ pDCs (Figure 18F) were 
identified among the groups.  
3.2.5 Hematopoietic Cybb deficiency did not alter the T cell compartment 
Hematopoietic Cybb deficiency did not substantially impact the lymphoid compartment. All 
genotypes exhibited indistinguishable total percentages of TCRβ+ T cells (Figure 19A). The 
percentages of CD4+ T cells and CD4+CD44+CD62L- activated T cells were also not 
significantly different across all groups (Figure 19B). Similar results were obtained for naive and 
activated CD8+ T cells (Figure 19C).  
3.2.6 Stromal Cybb deficiency did not drive SLE kidney disease 
Cybb-deficient SLE prone mice reconstituted with wild-type bone marrow did not develop 
exacerbated glomerulonephritis (Figure 20A). Aggravated interstitial nephritis was not observed 
in SLE prone Cybb-/- recipients reconstituted with wild-type bone marrow (Figure 20B). 
Heterozygous (Cybb+/-) female SLE prone mice developed exacerbated manifestations of SLE, 
an observation that extends to female patients that carry one copy of the loss of function CYBB 
allele. To assess the threshold of Cybb deficiency that is required to drive SLE, we generated 
mixed bone marrow chimeras. Reconstitution of wild-type MRL.Faslpr recipients with 20% of 
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Cybb-/- bone marrow was not sufficient to worsen glomerulonephritis or interstitial nephritis 
(Figure 20C and D). The 80-20 mixed bone marrow chimeras represent an important negative 
control for section 3.3. 
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Figure 13. Assembly of the phagocyte NADPH oxidase. 
The phagocyte NADPH oxidase was the first identified and is the best studied member of the NOX family. It is 
highly expressed in granulocytes and monocyte/macro- phages and contributes to killing of microbes. In resting 
neutrophil granulocytes, CYBB (NOX2) and p22phox are found primarily in the membrane of intracellular vesicles. 
They exist in close association, co-stabilizing one another. Upon activation, there is an exchange of GDP for GTP on 
RAC leading to its activation. Phosphorylation of the cytosolic p47phox  (NCF1) subunit leads to conformational 
changes allowing interaction with p22phox. The movement of p47phox brings with it the other cytoplasmic 
subunits, p67phox  (NCF2) and p40phox, to form the active CYBB enzyme complex. Once activated, there is a 
fusion of CYBB-containing vesicles with the plasma membrane or the phagosomal membrane. The active enzyme 
complex transports electrons from cytoplasmic NADPH to extracellular or phagosomal oxygen to generate 
superoxide (O2-) Adapted from: Bedard K, and Krause KH. The NOX family of ROS-generating NADPH oxidases: 
physiology and pathophysiology. Physiol Rev. 2007;87(1):245-313 
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Figure 14. Hematopoietic Cybb deficiency decreases survival and exacerbated kidney disease in the 
MRL.Faslpr SLE mouse model. 
(A) Kaplan-Meier survival curve of female MRL.Faslpr recipients reconstituted with Cybb+/+ (n=8) or Cybb-/- (n=7) 
bone marrow (B) Proteinuria. (C) Glomerulonephritis scores (top panel) and interstitial nephritis scores (bottom 
panel). (D) Representative images of H&E-stained kidney sections showing glomeruli and interstitial infiltrates from 
MRL.Faslpr recipients receiving control (top panel) or Cybb-/- bone marrow. Weights are represented as a function of 
Cybb-genotype and gender at 16 weeks post-irradiation. Bars represent the median and each dot represents and 
individual mouse. A log-rank test (A) or a two-tailed Mann-Whitney test (B-D) was performed to determine 
statistical significance within each gender (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=24 to 
40 mice per group unless otherwise indicated). 
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Figure 15. Increased splenomegaly in MRL.Faslpr mice with a hematopoietic Cybb defect. 
(A) Spleen weight. (B) Axillary lymph node weights. Weights are represented as a function of Cybb-genotype and 
gender at 16 weeks post-irradiation. Data representation, number of mice, and statistics are as in Figure 14. 
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Figure 16. Increased anti-RNA but decreased anti-nucleosome titers in MRL.Faslpr mice with a hematopoietic 
Cybb defect. 
(A-D) Serum anti-RNA (A), anti-Sm (B), anti-nucleosome (C), rheumatoid factor (D), antibody titers at 16 weeks 
post irradiation. The dotted line denotes the upper limit of quantitation. Data representation and statistics are as in 
Figure 14 (n=24 to 40 mice per group). 
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Figure 17. Hematopoietic Cybb deficiency did not change the B cell or AFC compartments. 
(A-D) Numbers of Igκ (A), IgG1 (B), IgG2a (C), and IgM (D) antibody forming cells (AFCs) per spleen as 
determined by ELISpot. (E) Percentages of live CD19+ total B cells. (F) Percentages of live cells that are TCRβ− 
CD44+ CD138+ intracellular κ+ AFCs. Data representation, number of mice, and statistics are as in Figure 13. In 
panels E and F, bar graphs are represented as the mean ± SEM and a two-tailed Welch’s T test was performed to 
determine statistical significance within each gender (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** 
p≤0.0001; n=24-40 mice per group).   
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Figure 18. Expanded myeloid compartment in MRL.Faslpr mice with a hematopoietic Cybb defect. 
(A) Percentages of live bone marrow (BM) CD11b+ Ly6G+ neutrophils. (B) Percentages of BM CD11b+ GR1low-int 
F4/80+ macrophages.  (C) Percentages of live CD11b+ Ly6G+ neutrophils in the spleen. (D) Percentages of splenic 
CD11b+ GR1low-int F4/80+ macrophages. (E) Percentages of live CD19- MHCII+ CD11c+ conventional dendritic cells 
and (F) CD19- BST2+ CD11c+ plasmacytoid dendritic cells. Bar graphs are represented as the mean ± SEM and a 
two-tailed Welch’s T test was performed to determine statistical significance within each gender (* indicates p≤0.05, 
** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=24-40 mice per group).   
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Figure 19. Hematopoietic Cybb deficiency had little impact on the T cell compartment. 
(A) Percentages of live TCRβ+ total T cells. (B) Percentages of live TCRβ+ CD4+ T cells (left panel) and of CD4+ 
CD44+ CD62L- activated T cells (right panel). (C) Percentages of live TCRβ+ CD8+ T cells (left panel) and of CD8+ 
CD44+ CD62L- activated T cells (right panel). Data representation, number of mice, and statistics are as in Figure 
18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 61 
 
 
Figure 20. Stromal Cybb deficiency did not affect glomerulonephritis or interstitial nephritis. 
(A) Glomerulonephritis scores and (B) interstitial nephritis scores of the reciprocal bone marrow chimera cohort 
(n=6 to 8 mice per group). (C) Glomerulonephritis scores and (D) interstitial nephritis scores of the 20/80 mixed 
bone marrow chimera cohort (n=9 to 12 mice per group). Scores are represented as a function of Cybb-genotype and 
gender at 12 weeks (A & B) and 16 weeks (C & D) post irradiation. Data representation and statistics are as in 
Figure 14.  
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3.3 DEVELOPMENT OF A NOVEL CHIMERA SYSTEM TO DELETE CYBB IN 
THE MYELOID COMPARTMENT 
Our data convincingly show that hematopoietic Cybb deficiency was sufficient to drive SLE 
pathogenesis. The phenotype that we observed in our chimera system excludes a role for stromal 
Cybb deficiency as a major contributor responsible for the exacerbated lupus observed in the 
Cybb global knockout MRL.Faslpr system. Nonetheless, NADPH oxidase can constrain 
inflammation (82, 83) by neutrophil (84, 85), macrophage (86), and/or lymphocyte-dependent 
(87, 88) mechanisms. To further assess the cell specific role of Cybb deficiency in SLE, we 
generated a novel chimera strategy to delete Cybb selectively in the myeloid compartment, 
specifically in neutrophils and macrophages. We first chose to target the myeloid compartment 
as Cybb is highly expressed in phagocytes and has well characterized immunoregulatory 
functions in this compartment, including the modulation of neutrophil death and subsequent 
clearance by macrophages.  
To delete Cybb selectively in the myeloid compartment, we crossed the LysM-Cre (182) 
to the Rosa26-eGFP-DTA (183) strains on the MRL.Faslpr background (∆LysM). Removal of the 
transcriptional stop site will only occur in LysM expressing cells, such as neutrophils and 
macrophages, leading to expression of a diphtheria toxin subunit and selective killing of that cell.  
5-7 week old MRL.Faslpr recipients were irradiated and reconstituted with an 80:20 mixture of 
∆LysM and Cybb-deficient (∆LysM Cybb-/-) or Cybb-sufficient (∆LysM Cybb+/+) bone marrow. 
In the reconstituted irradiated MRL.Faslpr recipient, we expect ~100% of neutrophils, 50% of 
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macrophages, and 20% of the remaining hematopoietic compartment to be Cybb-deficient 
(Figure 21). Importantly, reconstitution of wild-type MRL.Faslpr recipients with 20% of Cybb-/- 
bone marrow was not sufficient to worsen glomerulonephritis or interstitial nephritis (Figure 20C 
and D). As a positive control known to develop exacerbated manifestations of SLE, Cybb-
sufficient MRL.Faslpr SLE prone mice were irradiated and reconstituted with Cybb-/- MRL.Faslpr 
bone marrow (red bars). SLE pathology was assessed in chimeric mice 16 weeks post irradiation.  
3.3.1 Cybb was effectively deleted in the myeloid compartment of ∆LysM Cybb-/- 
MRL.Faslpr mice 
Deletion of Cybb was quantitated by qPCR of genomic DNA acquired from FACS-sorted cell 
populations. Additionally, GFP expression was used as a surrogate measure of Cybb-sufficient 
reconstitution. Cells from the ∆LysM donor that either do not express Cre or escape Cre mediated 
recombination at the Rosa26-eGFP-DTA locus will survive and continue to express GFP. Cybb 
was efficiently deleted in splenic CD11b+Gr1+ neutrophils (88.09% ± 2.128) (Figure 22A). 
Consistent with the prior literature (184), deletion efficiency was 46.28% (± 2.026) in 
CD11b+F4-80+ splenic macrophages (Figure 22B). As expected, Cybb was not efficiently deleted 
in the B cell (30.72% ± 2.427) or T cell (16.1% ± 5.223) compartments. Of note, the deletion 
efficiency assessed by qPCR was different than the percentage of GFP+ T cells, with the latter 
underrepresenting the Cybb-sufficient contribution. It is likely that this is due to the presence of 
radioresistant T cells in the host, which would not express GFP. 
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3.3.2 Cybb deficiency in LysM expressing cells was sufficient to exacerbate SLE kidney 
disease 
Proteinuria was increased in ∆LsyM Cybb-/- MRL.Faslpr female mice (Figure 23A). No 
differences in the incidence or severity of dermatitis were observed amongst the groups (Figure 
23B). Cybb deficiency in LysM expressing cells exacerbated glomerular and interstitial nephritis 
in both male and female MRL.Faslpr mice (Figure 23C and D). Spleen weight was increased in 
male ∆LsyM Cybb-/- MRL.Faslpr mice, a finding not recapitulated in the female cohort (Figure 24 
A and B). Proteinuria, glomerulonephritis and interstitial nephritis scores were elevated in the 
positive control MRL.Faslpr recipients reconstituted with Cybb-/- bone marrow (Figure 23A, C, 
and D). 
3.3.3 Myeloid Cybb deficiency did not have a major impact on the anti-self response. 
∆LsyM Cybb genotype did not generally alter the autoantibody response. As expected, Anti-RNA 
antibody titers were elevated in male mice receiving 100% Cybb-/- MRL.Faslpr bone marrow 
(Figure 25A). We did not detect any change in anti-Sm (Figure 25B), anti-nucleosome (Figure 
25C), or rheumatoid factor (Figure 25D) titers across the groups.  
3.3.4 The AFC compartment was altered in SLE prone mice with a myeloid Cybb defect 
Total kappa Ig AFC ELISpots were elevated in male ∆LsyM Cybb-/- MRL.Faslpr mice (Figure 
26A). In male mice receiving 100% Cybb-/-  MRL.Faslpr bone marrow, total Ig kappa and IgG1 
AFCs were increased (Figure 26A and B). There were no statistically significant differences in 
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AFC ELISpots for the IgG2a and IgM isotypes (Figure 26C and D). Furthermore, ∆LsyM Cybb 
genotype did not affect the percentage of CD19+ B cells (Figure 26E). CD19low-int CD44+ 
CD138+ intracellular κhigh AFCs were elevated in female MRL.Faslpr recipients receiving ∆LsyM 
Cybb-/- bone marrow as assessed by flow cytometry, a finding not observed in the male cohort 
(Figure 26F). 
3.3.5 Cybb deficiency in LysM expressing cells did not alter the composition of the 
myeloid compartment in MRL.Faslpr mice 
The percentage of CD11b+Ly6G+ bone marrow neutrophils (Figure 27A) was elevated in male 
mice receiving 100% Cybb-/-  bone marrow compared to ∆LsyM Cybb+/+ negative controls. 
∆LsyM Cybb genotype did not impact the percentage of bone marrow CD11b+F4/80+Gr1low-int 
macrophages (Figure 27B). No statistically significant difference in splenic neutrophils or 
macrophages was observed (Figure 27C and D). Additionally, we did not find any changes in the 
percentages of CD19-CD11c+MHCII+ cDCs (Figure 27E) and CD19-BST2+ SiglecH+ pDCs with 
the exception that female MRL.Faslpr recipients receiving 100% Cybb/-  bone marrow had an 
increased percentage of pDCs compared to ∆LsyM Cybb+/+ negative controls (Figure 27F). 
3.3.6 Myeloid Cybb deficiency did not alter the T cell compartment 
Cybb deficiency in LysM expressing cells did not substantially impact the lymphoid 
compartment. All genotypes exhibited no statistical differences in the total percentages of TCRβ+ 
T cells (Figure 28A). The percentages of CD4+ T cells and CD4+CD44+CD62L- activated T cells 
were also not significantly different across all groups (Figure 28B). Similar results were obtained 
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for naive and activated CD8+ T cells (Figure 28C).  
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Figure 21. Chimera strategy to delete Cybb in the myeloid compartment of SLE prone mice. 
To generate a neutrophil and macrophage-deficient donor we crossed the LysM-Cre to the Rosa26-eGFP-DTA 
strains on the MRL.Faslpr background (∆LysM). Cre mediated removal of the transcriptional stop site will only occur 
in LysM expressing cells leading to expression of a diphtheria toxin subunit and cell death. 6-7 week old MRL.Faslpr 
recipients were irradiated and reconstituted with an 80:20 mixture of ∆LysM and cybb-deficient (∆LysM Cybb-/-) or 
Cybb-sufficient (∆LysM Cybb+/+) bone marrow. In the reconstituted irradiated MRL.Faslpr recipient, we expect 
~100% of neutrophils, 50% of macrophages, and 20% of the remaining hematopoietic compartment to be Cybb-
deficient. 
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Figure 22. Cybb was effectively deleted in neutrophils and macrophages from ∆LysM Cybb-/- MRL.Faslpr mice. 
Cybb deletion efficiency was quantitated by qPCR of genomic DNA isolated from FACS sorted cells. GFP+ cells 
from the ∆LysM mice that escaped Cre mediated deletion served as a surrogate for Cybb-sufficient reconstitution.  
(A) Cybb deletion efficiency in n neutrophils (left panel) and the % GFP+ splenic neutrophils (right panel). (B) Cybb 
deletion efficiency in macrophages (left panel) and the % GFP+ splenic macrophages (right panel).  (C) Cybb 
deletion efficiency in B cells (left panel) and the % GFP+ splenic B cells (right panel).  (D) Cybb deletion efficiency 
in T cells (left panel) and the % GFP+ splenic T cells (right panel).  A one-way ANOVA with post-hoc Holm-Sidak 
test was performed to determine statistical significance (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** 
p≤0.0001; n=4 to 12 mice per group). 
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Figure 23. Myeloid Cybb deficiency was sufficient to exacerbate SLE kidney disease. 
(A) Proteinuria. (B) Dermatitis.  (C) Glomerulonephritis scores (top panel) and interstitial nephritis scores (bottom 
panel). (D) Representative images of H&E-stained kidney sections showing glomeruli and interstitial infiltrates from 
MRL.Faslpr recipients receiving control (top panel) or ∆LysM cybb-/- bone marrow. Scores are represented as a 
function of Cybb-genotype and gender at 16 weeks post-irradiation. Bars represent the median and each dot 
represents and individual mouse. A Kruskal-Wallis test with post-hoc Dunn’s test was performed to determine 
statistical significance within each gender (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=9 to 
22 mice per group). 
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Figure 24. Cybb deficiency in LysM expressing cells did not impact splenomegaly or lymphadenopathy in 
MRL.Faslpr mice. 
(A) Spleen weight. (B) Axillary lymph node weights. Weights are represented as a function of Cybb-genotype and 
gender at 16 weeks post-irradiation. Data representation, number of mice, and statistics are as in Figure 23. 
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Figure 25. Myeloid Cybb deficiency did not alter the anti-self response. 
(A-D) Serum anti-RNA (A), anti-Sm (B), anti-nucleosome (C), rheumatoid factor (D) antibody titers at 16 weeks 
post irradiation. Data representation and statistics are as in Figure 23. 
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Figure 26. Igκ AFCs were increased in SLE prone mice with a myeloid Cybb defect 
Numbers of Igκ (A), IgG1 (B), IgG2a (C), and IgM (D) antibody forming cells (AFCs) per spleen as determined by 
ELISpot. (E) Percentages of live CD19+ total B cells. (F) Percentages of live cells that are TCRβ− CD44+ CD138+ 
intracellular κ+ AFCs. Data representation, number of mice, and statistics are as in Figure 23. In panels E and F, bar 
graphs are represented as the mean ± SEM and a two-tailed Welch’s T test was performed to determine statistical 
significance within each gender (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=8 to 20 mice 
per group).   
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Figure 27. Cybb deficiency in LysM expressing cells did not alter the composition of the myeloid compartment 
in MRL.Faslpr mice. 
(A) Percentages of live bone marrow (BM) CD11b+ Ly6G+ neutrophils. (B) Percentages of BM CD11b+ GR1low-int 
F4/80+ macrophages.  (C) Percentages of live CD11b+ Ly6G+ neutrophils in the spleen. (D) Percentages of splenic 
CD11b+ GR1low-int F4/80+ macrophages. (E) Percentages of live CD19- MHCII+ CD11c+ conventional dendritic cells 
and (F) CD19- BST2+ CD11c+ plasmacytoid dendritic cells. Bar graphs are represented as the mean ± SEM and a 
two-tailed Welch’s T test was performed to determine statistical significance within each gender (* indicates p≤0.05, 
** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=8-20 mice per group).   
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Figure 28. Myeloid Cybb deficiency did not alter the T cell compartment. 
(A) Percentages of live TCRβ+ total T cells. (B) Percentages of live TCRβ+ CD4+ T cells (left panel) and of CD4+ 
CD44+ CD62L- activated T cells (right panel). (C) Percentages of live TCRβ+ CD8+ T cells (left panel) and of CD8+ 
CD44+ CD62L- activated T cells (right panel). Data representation, number of mice, and statistics are as in Figure 
27. 
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3.4 GENERATION OF THE CYBB CONDITIONAL KNOCKOUT MOUSE ON THE 
MRL.FASLPR BACKGROUND USING CRISPR-CAS9 
The cell specific role of CYBB in SLE has significant implications as to the mechanism by 
which CYBB contributes to autoimmunity. To investigate the tissue-specific function of CYBB 
in lupus, we generated a Cybb conditional allele directly on the MRL.Faslpr background using 
CRISPR-Cas9 technology (185) coupled with in vitro fertilization (186) (Figure 16A). In vitro 
fertilization was used to generate single cell MRL.Faslpr embryos. Resulting embryos were 
injected at the pronuclear stage with single guide RNAs (sgRNA), Cas9 endonuclease, and 
single-stranded oligo (ssODN) repair templates to edit the murine genome.  
3.4.1 CRISPR-Cas9 targeting strategy to generate the Cybb conditional knockout mouse 
on an autoimmune background 
We developed a workflow (Figure 29A) to insert two loxP sites flanking exon 4 of Cybb (Figure 
29B). We chose to target exon 4 as it codes for a critical transmembrane domain that binds 
p47phox and heme groups. Following Cre-mediated deletion of exon 4, splicing of exon 3 into 
exon 5 would result in a frameshift generating a premature stop codon in exon 5. Two sgRNAs 
were used to generate double-stranded breaks flanking exon 4 of Cybb. The resulting double-
stranded breaks were repaired using ssODNs harboring a loxP and an EcoR1 restriction site to 
facilitate screening. (Figure 29B). One founder had correct insertion of a loxP site in intron 3 
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(Figure 29C; upper panel) with concomitant insertion of a loxP sequence in intron 4. However, 
we identified a one base pair deletion in the Cre binding arm of the intron 4 loxP site (Figure 
29C; lower panel). Based on in vitro studies showing that mutations in the loxP arms can be 
tolerated (187), we proceeded to test the functionality of this floxed allele in vivo by crossing it 
to the LysM-Cre and Mrp8-Cre strains as described later in this chapter.  
3.4.2 A serial targeting approach to make Cybb conditional knockout mouse on the 
MRL.Faslpr strain using CRISPR-Cas9  
It is possible that the mutated loxP site described above does not work as well as the wild-type 
version. To address this concern, we moved forward to generate a Cybb-floxed allele with two 
wild-type loxP sites. At present, we find, as do many others attempting to produce mutant mice 
with CRISPR-Cas9 technology, that the efficiency of accurate homology directed repair (HDR) 
is too low to consistently produce conditional alleles in a single step. Correct integration of two 
loxP sites requires the simultaneous occurrence of two unlikely events. We overcame this 
limitation by employing a strategy to insert loxP sites in two steps. The first round of 
gene editing yielded a mouse with a single intact loxP site in intron 4 but no loxP site in intron 
3. We took advantage of this founder and used in vitro fertilization coupled with CRISPR-
Cas9 to insert the second loxP site into intron 3 of Cybb (Figure 30). As the first round of 
CRISPR-Cas9 gene editing resulted in an indel at the intron 3 target site, we designed a 
modified sgRNA to account for the new target site sequence. One founder was identified 
with two wild-type loxP sites flanking exon 4 (Figure 31). 
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Figure 29. Generation of the Cybb-floxed allele on the MRL.Faslpr background using CRISPR-Cas9 and in 
vitro fertilization. 
(A) Workflow to genetically modify MRL.Faslpr mice using CRISPR-Cas9.  (B) CRISPR-Cas9 strategy to generate
the Cybb-floxed allele. (C) Sequencing chromatograms of the two loxP sites flanking exon 4 in the Cybb-floxed
MRL.Faslpr founder.
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Figure 30. Schematic of a serial targeting approach to generate the Cybb-floxed MRL.Faslpr allele by 
CRISPR-Cas9 mediated gene editing. 
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Figure 31. A serial targeting strategy successfully generated a Cybb-floxed allele on the MRL.Faslpr 
background with two wild-type loxP sites. 
Sequencing chromatograms of the two loxP sites flanking exon 4 in the Cybb-floxed MRL.Faslpr founder mouse 
generated by the serial CRISPR-Cas9 targeting strategy. 
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3.5 ANALYSIS OF CYBB DELETION IN MACROPHAGES AND NEUTROPHILS 
IN THE INITIATION AND PROGRESSION OF SLE USING A CONDITIONAL 
KNOCKOUT APPROACH 
To confirm the role of macrophage and neutrophil Cybb deletion in SLE identified by our 
chimera approached, we generated homozygous Cybb-floxed mice that were also heterozygous 
or homozygous for LysM-Cre. LysM-Cre negative Cybb-floxed littermates served as a negative 
control in this cohort. SLE pathology was assessed at 19-20 weeks of age.  
3.5.1 Cybb is effectively deleted in the myeloid compartment of male LysM-Cre positive 
Cybb-floxed MRL.Faslpr mice but not in females 
Cybb deletion was measured by qPCR of genomic DNA acquired from FACS-sorted immune 
cell populations. Cybb was efficiently deleted in splenic CD11b+Gr1+ neutrophils isolated from 
male Cybbfl/y LysM-Cre+/- (%72.51 ±1.46) and Cybbfl/y LysM-Cre+/+ MRL.Faslpr mice (92.47% 
±1.23) (Figure 32A).  LysM-Cre is known to be less efficient in targeting macrophages than 
neutrophils. Paralleling this observation, Cybb deletion in Cybbfl/fl LysM-Cre+/- CD11b+F4-80+ 
splenic macrophages was 31% (± 3.016). LysM-Cre homozygosity increased Cybb deletion in 
Cybbfl/fl LysM-Cre+/+ macrophages to 53.38% (±4.517) (Figure 32B). Cybb deletion efficiency 
was significantly lower in the female cohort. In female Cybbfl/fl LysM-Cre+/- mice, the mean Cybb 
deletion in neutrophils was 46.81% (±2.59) (Figure 32A). Similar to the male cohort, LysM-Cre 
homozygosity increased Cybb deletion in Cybbfl/fl LysM-Cre+/+ neutrophils to 79.82% (±1.69) 
(Figure 32A). Surprisingly, no detectible deletion of Cybb was measured in splenic macrophages 
from female Cybbfl/fl LysM-Cre+/- mice (Figure 32B). However, Cybbfl/fl LysM-
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Cre+/+macrophages isolated from female mice had a deletion efficiency of 24.47% (±9.82) 
(Figure 32B). Of note, LysM-Cre homozygous mice were not included in the presented 
downstream analyses (Figure 32B). LysM-Cre is a site directed knockin resulting in a non-
functional allele. Therefore, homozygotes are LysM-deficient, potentially confounding analysis 
and interpretation of any observed phenotype.  
3.5.2 LysM Cybb deficiency worsened renal disease in female MRL.Faslpr mice 
There was a trend towards increased proteinuria in female Cybbfl/fl LysM-Cre+/- MRL.Faslpr mice 
at 14 and 20 weeks of age (Figure 33A and B). Concordantly, glomerulonephritis and initial 
nephritis was exacerbated in this group (Figure 33C and D). We did not observe any differences 
in proteinuria or histological assessment of nephritis in the male cohort (Figure 33C and D).  No 
differences in splenomegaly or lymphadenopathy were identified among the groups (Figure 33E 
and F).    
3.5.3 Cybb deficiency in the myeloid compartment had a minimal effect on the anti-self 
response 
Autoantibody titers were not affected by conditional Cybb deficiency in LysM expressing cells. 
We did not observe any change in anti-RNA antibody (Figure 34A), anti-Sm antibody (Figure 
34B), anti-nucleosome antibody (Figure 34C), or rheumatoid factor (Figure 34D) titers in 
Cybbfl/fl LysM-Cre+/- MRL.Faslpr mice compared to controls. Male Cybbfl/y LysM-Cre+/- 
MRL.Faslpr mice had an increase in the percentage of CD19+ B cells (Figure 34E) and a trend 
towards an elevated percentage of CD19low-int CD44+ CD138+ intracellular κhigh AFCs (Figure 
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43F; p=0.069).  As this finding was not recapitulated in the female cohort, and correlates neither 
with altered antibody profile nor disease severity, its biological significance is unclear. 
3.5.4 Bone marrow neutrophils and macrophages were reduced in female Cybbfl/fl LysM-
Cre+/- MRL.Faslpr mice 
Conditional Cybb deficiency in LysM expressing cells altered the myeloid compartment in 
female MRL.Faslpr mice. The percentage of bone marrow CD11b+ GR1+ neutrophils and 
CD11b+F4/80+Gr1low-int macrophages were reduced in Cybbfl/fl LysM-Cre+/- females compared to 
controls (Figure 35A and B). Reciprocally, the percentage of splenic neutrophils was expanded 
in this same group (Figure 35C). No statistically significant differences in splenic macrophages 
were identifed (Figure 35D). Male Cybbfl/y LysM-Cre+/- mice exhibited an increased percentage 
of CD19-CD11c+MHCII+ cDCs, a finding not observed in the female cohort. We did not identify 
any changes in pDCs amongst the groups.  
3.5.5 Conditional LysM Cybb deficiency did not significantly alter the T cell compartment 
Similar to our chimera studies, conditional Cybb deficiency in macrophages and neutrophils had 
little impact on the lymphoid compartment. All genotypes exhibited no statistical differences in 
the total percentages of TCRβ+ T cells (Figure 36A). The percentages of CD4+ T cells and 
CD4+CD44+CD62L- activated T cells were also not significantly different across all groups 
(Figure 36B). No changes in the percentages of naive and activated CD8+ T cells were observed 
(Figure 36C).  
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To summarize our interim findings, hematopoietic but not stromal Cybb deficiency 
exacerbated multiple manifestations of lupus in the MRL.Faslpr model. Moreover, employing a 
chimera approach to delete Cybb in the myeloid compartment was sufficient to exacerbate SLE 
renal disease. Taken together, our data convincingly highlights neutrophil and/or macrophage 
CYBB as a critical regulator of autoimmunity. 
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Figure 32. Cybb was effectively deleted in the myeloid compartment of male LysM-Cre positive Cybb-floxed 
MRL.Faslpr mice but not in females. 
Cybb deletion efficiency in n neutrophils (A) and macrophages (B). A two-tailed Welch’s T test was performed to 
determine statistical significance within each gender (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** 
p≤0.0001; n=5 to 8 mice per group). 
85 
Figure 33. Conditional Cybb deletion in the myeloid compartment exacerbated glomerulonephritis and 
interstitial nephritis in female MRL.Faslpr mice. 
(A) Proteinuria at 14 weeks of age. (B) Proteinuria at 20 weeks of age. (C) Glomerulonephritis scores and (D)
Interstitial nephritis scores. (E) Spleen Weight. (F) Axillary lymph node weights. Scores and weights are
represented as a function of Cybb-flox LysM-Cre genotype and gender at 20 weeks of age unless otherwise
indicated. Bars represent the median and each dot represents and individual mouse. A one-tailed Mann-Whitney test
was performed to determine statistical significance within each gender (* indicates p≤0.05, ** p≤0.01, *** p≤0.001,
and **** p≤0.0001; n=14 to 24 mice per group unless otherwise indicated).
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Figure 34. Cybb deficiency in the myeloid compartment did not substantially impact the anti-self response. 
(A-D) Serum anti-RNA (A), anti-Sm (B), anti-nucleosome (C), rheumatoid factor (D), antibody titers at 20 weeks of 
age (E) Percentages of live CD19+ total B cells. (F) Percentages of live cells that are TCRβ− CD44+ CD138+ 
intracellular κ+ AFCs. Data representation, number of mice, and statistics are as in Figure 33. In panels E and F, bar 
graphs are represented as the mean ± SEM and a Welch’s T test was performed to determine statistical significance 
within each gender (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=14 to 24 mice per group).   
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Figure 35. Reduced bone marrow neutrophils and macrophages in female Cybbfl/fl LysM-Cre+/- MRL.Faslpr 
mice.  
(A) Percentages of live bone marrow (BM) CD11b+ Ly6G+ neutrophils. (B) Percentages of BM CD11b+ GR1low-int
F4/80+ macrophages.  (C) Percentages of live CD11b+ Ly6G+ neutrophils in the spleen. (D) Percentages of splenic
CD11b+ GR1low-int F4/80+ macrophages. (E) Percentages of live CD19- MHCII+ CD11c+ conventional dendritic cells
and (F) CD19- BST2+ CD11c+ plasmacytoid dendritic cells. Bar graphs are represented as the mean ± SEM and a
Welch’s T test was performed to determine statistical significance within each gender (* indicates p≤0.05, **
p≤0.01, *** p≤0.001, and **** p≤0.0001; n=14 to 24 mice per group).
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Figure 36. Conditional myeloid Cybb deficiency did not significantly alter the T cell compartment. 
(A) Percentages of live TCRβ+ total T cells. (B) Percentages of live TCRβ+ CD4+ T cells (left panel) and of CD4+ 
CD44+ CD62L- activated T cells (right panel). (C) Percentages of live TCRβ+ CD8+ T cells (left panel) and of CD8+ 
CD44+ CD62L- activated T cells (right panel). Data representation, number of mice, and statistics are as in Figure
35.
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3.6 EMPLOYING A CONDITIONAL KNOCKOUT APPROACH TO ASSESS 
NEUTROPHIL SPECIFIC CYBB DELETION IN SLE PATHOGENESIS 
The tools utilized thus far do not decipher the differential contribution of neutrophil versus 
macrophage CYBB in disease. Here, we utilize Mrp8-Cre (188) to specifically delete Cybb in 
neutrophils by crossing the Cybb-floxed allele to Mrp8-Cre. Taken together with our prior data, 
these studies will allow us to deduce the differential contribution of macrophage and neutrophil 
CYBB to systemic autoimmunity. SLE pathology was assessed at 18 weeks of age. Of note, the 
data presented here is preliminary and this line of investigation is still in progress. 
3.6.1 Neutrophil Cybb deficiency exacerbated renal disease in male MRL.Faslpr mice 
While no differences in urine protein were observed in the female cohort, male Cybbfl/fl Mrp8-
Cre+/- MRL.Faslpr mice had a trend towards increased proteinuria at 18 weeks of age (Figure 
37A). No differences in the incidence of dermatitis were detected amongst the groups (Figure 
37B). Glomerulonephritis was more severe in Cybbfl/y Mrp8-Cre+/- male SLE prone mice but 
interstitial nephritis remained unaffected (Figure 37C and D). However, no differences in 
glomerulonephritis or interstitial nephritis were identified in female Cybbfl/flMrp8-Cre+/- 
MRL.Faslpr mice (Figure 37C and D). Conditional Cybb deficiency in neutrophils increased 
spleen but not axillary lymph node weights in male SLE-prone mice (Figure 37E and F; 
p=0.0576).  
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3.6.2 Conditional Cybb deletion in neutrophils did not alter the anti-self response in SLE 
prone mice 
Autoantibody titers were not affected by conditional Cybb deficiency in neutrophils. We did not 
observe any change in anti-RNA antibody (Figure 26A), anti-Sm antibody (Figure 26B), anti-
nucleosome antibody (Figure 38C), or rheumatoid factor (Figure 38D) titers among the groups. 
No differences in in the percentages of CD19+ B cells (Figure 38E) or CD19low-int CD44+ 
CD138+ intracellular κhigh AFCs (Figure 38F) were identified in Cybbfl/fl Mrp8-Cre+/- MRL.Faslpr 
mice compared to controls.  
3.6.3 Neutrophil specific Cybb deletion did not alter the composition of the myeloid 
compartment in MRL.Faslpr mice 
Since the myeloid compartment was expanded in the setting of hematopoietic Cybb deficiency, 
we explored whether conditional deletion of Cybb in neutrophils changes the myeloid 
compartment. The percentages of bone marrow CD11b+ GR1+ neutrophils and macrophages 
were not altered in Cybbfl/fl Mrp8-Cre+/- MRL.Faslpr mice compared to controls (Figure 39A and 
B). No statistically significant differences in splenic CD11b+ GR1+ neutrophils (Figure 39C) or 
CD11b+F4/80+Gr1low-int macrophages were observed (Figure 39D). Cybbfl/fl Mrp8-Cre+/- did not 
have any impact on the percentage of CD19-CD11c+MHCII+ (Figure 39E) or CD19-BST2+
SiglecH+ pDCs (Figure 39F). 
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3.6.4 Neutrophil specific Cybb deletion does not alter the T cell compartment in 
MRL.Faslpr mice  
Concordant with our prior studies, conditional Cybb deficiency in neutrophils did not impact the 
lymphoid compartment. No statistical differences in the total percentages of TCRβ+ T cells were 
observed (Figure 40A). Cybb deletion in neutrophils did not significantly change the percentages 
of CD4+ T cells and CD4+CD44+CD62L- activated T cells across all groups (Figure 40B). 
Additionally, we did not observe any differences in the percentages of naive and activated CD8+ 
T cells (Figure 40C).  
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Figure 37. Neutrophil Cybb deficiency exacerbated glomerulonephritis and increased splenomegaly in male 
MRL.Faslpr mice. 
(A) Proteinuria. (B) Dermatitis.  (C) Glomerulonephritis scores. (D) Interstitial nephritis scores. (E) Spleen Weight.
(F) Axillary lymph node weights. Scores and weights are represented as a function of Cybb-flox LysM-Cre genotype
and gender at 18 weeks of age. Bars represent the median and each dot represents and individual mouse. A two-
tailed Mann-Whitney test was performed to determine statistical significance within each gender (* indicates
p≤0.05, ** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=6 to 12 mice per group unless otherwise indicated).
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Figure 38. Conditional Cybb deletion in neutrophils has no impact on the anti-self response in SLE prone 
mice.  
(A-D) Serum anti-RNA (A), anti-Sm (B), anti-nucleosome (C), rheumatoid factor (D), antibody titers at 20 weeks of 
age (E) Percentages of live CD19+ total B cells. (F) Percentages of live cells that are TCRβ− CD44+ CD138+ 
intracellular κ+ AFCs. Data representation, number of mice, and statistics are as in Figure 37. In panels E and F, bar 
graphs are represented as the mean ± SEM and a two-tailed Welch’s T test was performed to determine statistical 
significance within each gender (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=6 to 12 mice 
per group).   
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Figure 39. Neutrophil specific Cybb deletion did not change the percentages of neutrophils, macrophages or 
DCs in MRL.Faslpr mice.  
(A) Percentages of live bone marrow (BM) CD11b+ Ly6G+ neutrophils. (B) Percentages of BM CD11b+ GR1low-int
F4/80+ macrophages.  (C) Percentages of live CD11b+ Ly6G+ neutrophils in the spleen. (D) Percentages of splenic
CD11b+ GR1low-int F4/80+ macrophages. (E) Percentages of live CD19- MHCII+ CD11c+ conventional dendritic cells
and (F) CD19- BST2+ CD11c+ plasmacytoid dendritic cells. Bar graphs are represented as the mean ± SEM and a
two-tailed Welch’s T test was performed to determine statistical significance within each gender (* indicates p≤0.05,
** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=6 to 12 mice per group).
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Figure 40. Neutrophil specific Cybb deletion did not alter the T cell compartment in MRL.Faslpr mice. 
(A) Percentages of live TCRβ+ total T cells. (B) Percentages of live TCRβ+ CD4+ T cells (left panel) and of CD4+ 
CD44+ CD62L- activated T cells (right panel). (C) Percentages of live TCRβ+ CD8+ T cells (left panel) and of CD8+ 
CD44+ CD62L- activated T cells (right panel). Data representation, number of mice, and statistics are as in Figure 
39. 
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3.7 DISCUSSION 
Here, we provide data that supports myeloid-expressed CYBB as a fundamental negative 
regulator of SLE pathogenesis. Multiple approaches employed in this study reinforce our 
findings. First, to identify the differential contribution of CYBB in the stromal and hematopoietic 
compartments, we used a reciprocal bone marrow chimera approach. Notably, we found that 
hematopoietic, but not stromal, Cybb deficiency is sufficient to exacerbate autoantibody 
production, lupus nephritis, and reduce survival in the MRL.Faslpr model. These findings 
highlight that Cybb deficiency in a hematopoietic cell subset was the likely driver of the 
observed phenotype. To home in on which compartment(s) CYBB deficiency exerts its 
regulatory function, we developed a novel chimera strategy to delete Cybb selectively in the 
myeloid compartment, specifically in neutrophils and macrophages. Cybb deletion in 
macrophages and neutrophils was sufficient to exacerbate glomerular and interstitial nephritis. In 
parallel, we generated a Cybb conditional allele directly on MRL.Faslpr background to enable 
further characterization of tissue-specific CYBB function in SLE. Conditional deletion of Cybb 
in macrophages and neutrophils using LysM-Cre partially recapitulated the phenotype that we 
observed in the chimera system. The mechanism by which myeloid Cybb deletion exacerbates 
SLE remains enigmatic but will be further explored in chapter 4. 
While our data implicates myeloid CYBB deficiency as responsible for exacerbating 
multiple manifestations of lupus, it is still an outstanding question whether absence of CYBB in 
the neutrophil and/or macrophage is the primary culprit. The role of CYBB in macrophages and 
neutrophils may not be mutually exclusive but the answer to this question does hint at the 
potential mechanisms by which CYBB modulates disease. If CYBB deficiency in the neutrophil 
is the major driver of lupus, it is potentially due to neutrophil death. Billions of neutrophils die 
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each day posing a major potential antigen load (91). In the context of CYBB deficiency, the 
neutrophil may die by a more immunogenic manner, such as catastrophic necrosis, programmed 
necroptosis, pyroptosis, or ferroptosis.  It is possible that in the absence of CYBB, the process of 
NET formation is obstructed, resulting in frustrated NET generation that could be uniquely 
immunogenic. Moreover, NADPH oxidase complex-dependent ROS can inhibit caspases (189) 
(190). In the absence of CYBB increased neutrophil apoptosis has been observed (189). 
Additionally, proteases, such as Cathepsins, are inhibited by CYBB generated ROS (191). As 
proteases are abundant in neutrophil granules and can be released upon neutrophil death into the 
extracellular environment, it is possible increased protease activity due to CYBB deficiency 
could generate neo self-antigens. A higher degree of residual protease activity following 
neutrophil death could also be a direct cause of increased tissue damage in the absence of 
neutrophil-expressed CYBB. Caspases are implicated in the processing of pro-inflammatory 
cytokines such as IL-1 family members. Abrogation of CYBB function can lead to increased 
production of functional IL-1β in CGD mice and humans (85, 90, 192, 193). If macrophage 
CYBB deficiency is responsible for exacerbated autoimmunity, it likely results from a failure of 
the macrophage to clear dead cells and resulting debris as addressed in the introduction of this 
chapter and further discussed in chapter 4.  
To date, the efficiency and specificity of existing myeloid Cre strains limits the ability to 
directly assess the differential contribution of myeloid subsets in murine models. For instance, 
others and we have shown that LysM-Cre efficiently targets neutrophils but variably targets 
macrophages populations. Using our chimera system, we attempted to assess the role of 
neutrophil Cybb deletion using the neutrophil specific Cre strains, Elane-Cre and Mrp8-Cre, 
along with LysM-Cre to generate a neutropenic primary donor. No phenotype was observed in 
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the chimera cohort using the ∆Elane (Elane-Cre+/- Rosa26-eGFP-DTA +/-) mouse as the primary 
chimera donor (data not shown). We assessed hematopoietic reconstitution in this cohort by 
using GFP as a surrogate to approximate Cybb sufficiency. Unfortunately, over 65% of the 
neutrophils were wild-type in this cohort (data not shown). Though Elane-Cre is specific to 
neutrophils it is known to have a poor efficiency. As Mrp8-Cre is specific and efficient at 
targeting neutrophils, we backcrossed this allele to the MRL.Faslpr background. To generate a 
neutropenic donor, we crossed the Mrp8-Cre MRL.Faslpr to the Rosa26-eGFP-DTA allele. The 
resulting ∆MRP8 (Mrp8-Cre+/- Rosa26-eGFP-DTA +/-) mice were not viable, likely due to the 
transient expression of Mrp8-Cre during embryonic development. As an alternative to the 
chimera strategy, we can use the Cybb conditional allele to specifically delete Cybb in 
neutrophils, bypassing the technical issues encountered in the chimera system. Here, we utilized 
Mrp8-Cre to specifically delete Cybb in neutrophils by crossing the Cybb-floxed allele to Mrp8-
Cre. Preliminary results are reported here and these studies remain ongoing. Taken together with 
our prior data, these studies will allow us to deduce the differential contribution of macrophage 
and neutrophil CYBB to systemic autoimmunity. 
Strikingly, although glomerular and interstitial nephritis was exacerbated in female mice 
upon conditional deletion of Cybb in LysM expressing cells, Cybb deletion in neutrophils was 
only ~40% and was nearly undetectable in macrophages. Cybb heterozygous MRL.Faslpr female 
mice do develop worse SLE. Importantly, 50% of cells in global Cybb heterozygotes are Cybb-
deficient due to inactivation of one X chromosome in female mice. The presence of Cybb-
sufficient cells do not confer protection in the heterozygotes, paralleling our observations in the 
chimera and conditional knockout system employed in this study. Preliminary data show a trend 
towards increased proteinuria in male mice with conditional deletion of Cybb solely in 
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neutrophils. These two findings, taken together with the phenotype observed in our chimera 
system, suggest that neutrophil Cybb deficiency may be the major driver of the phenotype. 
Cybb deficiency in the myeloid compartment, mediated by LysM-Cre in both our 
chimera and conditional knockout systems, does not fully recapitulate the Cybb global knockout 
or total hematopoietic chimera phenotype. There are several explanations that could account for 
this discrepancy. First, LysM-Cre does not efficiently target macrophages. Therefore, if the 
exacerbated disease observed in the global and hematopoietic Cybb knockouts is at least in part 
due to a function of CYBB in macrophages, we may only observe partial penetrance of the 
phenotype. As CYBB is expressed in other immune cell subsets and is known to exert regulatory 
functions in B and T cells important in the pathogenesis of lupus, it is possible that intact 
lymphocyte CYBB dampens disease severity in both the myeloid chimera and conditional 
knockout systems.  
Surprisingly, conditional deletion of Cybb in LysM expressing cells was lower than 
expected in female mice based on our previous experience and the reported literature (184). 
Cybb deletion in macrophages was nearly undetectable. It is possible that inactivation of one of 
the two X chromosomes prevents Cre from mediating recombination at the X-inactivated Cybb 
locus. Chromatin structure and modification can impact locus specific Cre mediated recombinase 
activity. Alternatively, the single base pair deletion in the intron 4 loxP site could reduce 
recombination efficiency, especially in the setting of an inefficient or poorly expressed Cre. 
Given that LysM-Cre efficiently deleted Cybb in the males, we believe this explanation to be less 
likely. Nevertheless, we will formally test this idea by repeating these experiments using the 
Cybb conditional allele with fully “wild-type” loxP sites on both sides. 
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 CYBB deficiency in human CGD patients is associated with severe recurrent bacterial 
and fungal infections (120). We do not believe that an infectious process is the primary driver of 
the exacerbated phenotype observed here. All cohorts were housed in a specific pathogen free 
facility and maintained on broad spectrum antibiotics for the duration of the experiment. All 
mice were cohoused such that mice of different genotypes would share microbial flora. The 
autoantibody profiles coupled with the glomerular and interstitial nephritis observed by histology 
are consistent with the SLE-like disease observed in MRL.Faslpr mice. Mice and humans that are 
NADPH oxidase functional heterozygotes are more susceptible to autoimmunity but not to 
infection. Exacerbated manifestations of SLE observed here are unlikely to be due to changes in 
the microbiome. Autoimmunity in MRL.Faslpr mice is not mediated by the microbiome (141). 
Ncf1m1j/m1J mice rederived in a germ-free facility are still more susceptible to inflammatory 
arthritis (181). Additionally, the total hematopoietic chimeras were performed at two different 
intuitions. Taken together, it is unlikely that either infections processes or changes in the 
microbiome are responsible for the more severe disease we observed in multiple systems.  
Aside from the insights into how CYBB regulates autoimmunity, we also made 
contributions to methods for mouse genetic engineering. We developed a workflow to employ 
Crispr-Cas9, in combination with in vitro fertilization, to generate a conditional knockout mouse 
directly on the MRL.Faslpr background. By conventional ES approaches it would take 1.5-2 years 
to generate a mouse of interest on either a mixed or C57BL/6 background and then an additional 
2 years to backcross the founder to an autoimmune mouse strain at an expense of nearly $50,000. 
The approach we adopted here revolutionizes the study of autoimmunity as we can generate the 
tools needed to test a hypothesis in a causative way in less than 4 months and at a fraction of the 
cost. Moreover, by generating the mouse of interest directly on an autoimmune strain, we 
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eliminate the possibility that linked alleles carried by backcrossing contribute to the observed 
phenotype. This approach can be extended to the generation of conventional knockouts, point 
mutants, and insertion of large constructs.  
Another significant finding of our work is that single base pair deletion in the Cre binding 
region of a loxP site can be tolerated, allowing for Cre mediated recombination in vivo. In male 
mice, the efficiency of LysM-Cre mediated deletion of the conditional Cybb allele with a single 
base pair deletion in the intron 4 loxp site is consistent with the reported literature (187). In vitro 
studies indicate that loxP mutations are tolerated in vitro (187). LoxP variants are frequently 
used within the scientific community. Further testing is required and ongoing to determine 
whether this conditional allele functions as efficiently as that with two wild-type loxP sites. This 
finding is important because point mutations in loxP sites are a common finding in conditional 
knockout animals generated by CRISPR-Cas9 and these founders could potentially still be used 
by the research community.  
Collectively the data we present here suggests that CYBB is protective in SLE due to a 
fundamental regulatory activity of CYBB in macrophages and/or neutrophils, highlighting 
CYBB as a target for further mechanistic study and therapeutic development. 
3.8 MATERIALS AND METHODS 
Mice. Cybb-deficient (Catalogue# 002365), LysM-Cre (Catalogue# 004781), Mrp8-Cre 
C57BL/6 (Catalogue# 021614) mice were purchased from the Jackson Laboratories and 
backcrossed to the MRL.Faslpr strain for at least 9 generations. Homozygosity for the H2k 
haplotype and the lpr mutation was verified by PCR. The Cybb-floxed MRL.Faslpr mice were 
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generated using CRISPR-Cas9 as detailed below. All mice were housed under specific-pathogen-
free (SPF) conditions. Animal studies were approved by the University of Pittsburgh Institutional 
Animal Care Use Committee. 
Generation of Chimeric Mice. Bone marrow cells were obtained from either Cybb-/- or wild-type 
MRL.Faslpr littermate control mice. Cells were incubated in ACK (Ammonium-Chloride-
Potassium) buffer for erythroid cell lysis and resuspended in injection buffer (1 × PBS, 10 mM 
Hepes, 2.5% acid citrate dextrose anticoagulant, and 0.5% penicillin/streptomycin). 5-7 week old 
Cybb-/- or Cybb+/+ MRL.Faslpr recipient mice received 750 cGy from a cesium irradiator and 
were reconstituted with 8X106 Cybb-/-  or Cybb+/+cells per mouse. The Cybb-sufficient controls 
used throughout chapter 3, were often the ∆LysM Cybb+/+ MRL.Faslpr mice described below. For 
the 80:20 mixed ratio bone marrow chimeras, wild-type MRL.Faslpr recipients received 
1.6X106 Cybb-/-  and 6.4X106 Cybb+/+ cells per mouse. SLE pathology was assessed at time 
points indicated in the figure legends. 
To delete Cybb selectively in the myeloid compartment, we crossed the LysM-Cre to the 
Rosa26-eGFP-DTA strains on the MRL.Faslpr background (∆LysM). The Rosa26-eGFP-DTA 
locus contains the gene for the diphtheria toxin fragment A (DTA) that is preceded by a loxP-
flanked STOP cassette so that expression of the toxin is restricted to those cells expressing Cre 
recombinase. Expression of DTA leads to the death of that cell. Bone marrow cells from Cybb-/-, 
Cybb+/+, and ∆LysM were isolated and processed as above. 6-7 week old MRL.Faslpr recipients 
were irradiated and reconstituted with a 80:20 mixture of ∆LysM and Cybb-deficient (∆LysM 
cybb-/-) or Cybb-sufficient (∆LysM cybb+/+) bone marrow.  
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Mice were treated prophylactically with trimethoprim and sulfadiazine diet to prevent 
occult infection. 
Generation of the Cybb-floxed allele on the MRL.Faslpr strain using CRISPR-Cas9. Cybb-
floxed mice were generated using CRISPR-Cas9 technology (185). Two loxP sites were inserted 
flanking exon 4 of Cybb (Figure 29B and Table 1) using ssODNs with a loxP and an Ecor1 
restriction to facilitate genotyping (Integrated DNA Technologies; Table 2).  
We selected a sgRNA in intron 3 and intron 4 of Cybb using a python script 
implementing the Fuzznuc algorithm (Emboss) to identify unique N20NGG sequences and their 
associated off-targets, allowing 0-4 mismatches (194). The output was further corroborated by 
the Cas-OFFinder algorithm (RGEN Tools). Potential off-targets (Supplemental Table 1) with 
three or fewer mismatches and those without mismatch in the seed sequence (13 bp adjacent to 
the PAM sequence) will be screened, by amplifying each off-target locus with a specific primer 
pair and sequencing the PCR product in founder mice.  
The sgRNA was generated from a double strand linear DNA template by annealing a 
target specific primer containing a T7 promoter, the Cybb target sequence (without PAM), and 
part of the tracrRNA sequence with a common primer comprising the full tracrRNA sequence 
(Supplemental Table 2). The annealed template was subjected to a fill in reaction and the double 
stranded product was amplified using the T7-19 and sgRNA-R primers (Table 1). The resulting 
dsDNA template was purified with the QIAquick PCR purification kit (Qiagen) and then 
transcribed using the MEGAshortscript T7 kit (Invitrogen). Capped Cas9 mRNA transcripts 
were produced from PmeI-linearized purified pcDNA3.3topo-T7-hCas9 using the mMESSAGE 
mMACHINE T7 ULTRA Kit (Life Technologies). The Cas9 mRNA and the sgRNA were 
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purified using the MEGAclear kit (Life Technologies) and eluted in nuclease-free water. Cas9 
mRNA and the gRNA integrity was confirmed using a 2100 Bioanalyzer (Agilent Technologies). 
MRL.Faslpr pronuclear-stage zygotes were generated by in vitro fertilization and microinjected 
with sgRNAs (50 ng/μl), Cas9 mRNA (100 ng/μl), and ssODN repair templates (0.5uM) by the 
Gene Targeting and Transgenic Core (University of Pittsburgh). Injected zygotes were cultured 
overnight and transferred to pseudopregnant CD1 recipient females to obtain potential founder 
mice. Mice were genotyped by PCR amplification of the target locus and Restriction Fragment 
Length Polymorphism (RFLP) analysis. Amplified PCR products were subsequently cloned into 
a sequencing vector (NEB) and sequenced to verify correct targeting. 
The founders were backcrossed to wild-type MRL.Faslpr mice (The Jackson Laboratory 
catalogue # 000485) for 2 generations.  
A serial targeting strategy to make Cybb conditional knockout mouse on the MRL.Faslpr strain 
using CRISPR-Cas9. The aforementioned strategy to generate a Cybb-floxed allele yielded one 
founder with an intact loxP site in intron 4. This founder mouse was backcrossed to wild-type 
MRL.Faslpr mice for two generations and sperm from the N2 males was used to 
generate MRL.Faslpr embryos, harboring the intro 4 loxP site, by in vitro fertilization. We used 
CRISRP-Cas9 to retarget intron 3 as outlined above. As a 1 base pair insertion was present in 
the intron 3 target sequence as a result of the first round of gene editing, we generated a 
modified sgRNA to account for the indel in the target sequence. CRISPR-Cas9 reagents 
were injected into MRL.Faslpr pronuclear-stage zygotes and resulting founders were screened 
as described above. 
Strategy to conditionally delete Cybb from macrophages and neutrophils in  MRL.Faslpr mice. LysM-Cre MRL.Faslpr mice were intercrossed with Cybbfl/wt or Cybbfl/y MRL.Faslpr ice. 
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Resulting LysM-Cre+/- Cybbfl/wt or LysM-Cre+/- Cybbfl/y MRL.Faslpr mice were then crossed 
with MRL.Faslpr Cybbfl/y males or Cybbfl/wt females respectively. To generate mice for 
experimental cohorts, LysM-Cre+/-Cybbfl/fl and LysM-Cre+/-Cybbfl/y were intercrossed. As an 
alternative breeding strategy, we intercrossed LysM-Cre+/- Cybbfl/fl to Cybbfl/y and LysM-Cre+/-
 Cybbfl/y to Cybbfl/fl.  This breeding strategy generated littermate controls for each group. SLE 
pathology was assessed at 19-20 weeks of age. Mice were treated prophylactically with 
trimethoprim and sulfadiazine diet to prevent occult infection. 
Strategy to conditionally delete cybb from neutrophils in MRL.Faslpr mice. Mrp8-Cre 
MRL.Faslpr mice were intercrossed with Cybbfl/wt or Cybbfl/y MRL.Faslpr mice. Resulting Mrp8-
Cre+/- Cybbfl/wt or Mrp8-Cre+/- Cybbfl/y MRL.Faslpr mice were then crossed 
with MRL.Faslpr Cybbfl/y males or Cybbfl/wt females respectively. To generate mice for 
experimental cohorts, we intercrossed Mrp8-Cre+/- Cybbfl/fl to Cybbfl/y and Mrp8-Cre+/- Cybbfl/y to 
Cybbfl/fl.  This breeding allowed us to use littermate controls for each group. SLE pathology was 
assessed at 18 weeks of age. Mice were treated prophylactically with trimethoprim and 
sulfadiazine diet to prevent occult infection. 
Quantitative PCR. For assessing deletion efficiency of Cybb, genomic DNA extracted from 
FACS sorted cells and used as template for qRT-PCR. qRT-PCR reactions were completed in 
triplicate using Kappa SYBR Green QPCR kit. The amount of Cybb in each sample was 
normalized to the unaffected gene Tlr9. Genomic DNA of the same cell type from Cybbfl/fl mice 
was used as undeleted control. Mice were 20 weeks old. Samples were run on a Roche Light 
cycler instrument. 
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Evaluation of SLE pathology. Refer to chapter 2 
Flow cytometry. Refer to chapter 2 
Autoantibody ELISAs. Refer to chapter 2 
Statistics. Statistical analysis was performed using Prism 7.0 (Graphpad). A Kruskal-Wallis test 
with post-hoc Dunn’s test, one or two-tailed Mann-Whitney U test, two-tailed Welch’s t test, and 
a log-rank test were performed where indicated and appropriate. A p value <0.05 was considered 
statistically significant. 
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Table 1. Primers for Cybb sgRNA generation 
Table 2. ssODN repair constructs to generate the Cybb-floxed allele 
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4.0  LC3-ASSOCIATED PHAGOCYTOSIS AND SLE: AN INVESTIGATION OF 
CYBB, RUBICON, AND IL-10 IN LUPUS PATHOGENESIS 
4.1 INTRODUCTION 
4.1.1 Dead cell clearance defects and SLE 
Loss of tolerance to nuclear antigens and the formation of autoantibodies to nucleic acids and 
nucleoproteins are hallmarks of SLE pathogenesis. While the sources of autoantigens in lupus 
remain enigmatic, a failure to adequately dispose of dead cells and resulting debris by 
macrophages is a leading possibility. Indeed, macrophages from a subset of lupus patients 
exhibit an impaired ability to phagocytose, a finding also observed in murine models (195-198). 
Paralleling these observations, SLE patients with leukemia undergoing pharmacological 
myeloablative therapy had greater accumulation of dead cells in the bone marrow compared non-
autoimmune control subjects (195). Moreover, the LE (Lupus Erythematous) cell, a typical 
histologic finding in SLE patients where a neutrophil or macrophage engulfed denatured nuclear 
debris, could represent an inability to properly degrade phagocytosed contents (199, 200).  
 There are several lines of evidence that link dead cell clearance pathways to the 
development of systemic autoimmunity in mice and in humans. C1q, a component of the C1 
complex, is critical for the classic complement pathway (201). Upon opsonization, C1q can bind 
 109 
dead cells, facilitating uptake by macrophages (201). Over 90% of patients with loss of function 
mutations in C1q develop a SLE-like disease (202, 203). C1q deficient autoimmune and non-
autoimmune mouse strains are subject to decreased survival, exacerbated renal disease, and 
autoantibody titers (204, 205). However, it should be noted that background genetics do alter this 
phenotype (204, 205). Apoptotic bodies have been identified in the glomeruli of C1q-deficient 
mice, further highlighting a defect in dead cell clearance in diseased animals (204).  
Apoptotic cells transfer phosphatidylserine (PS) from the inner leaflet of the plasma 
membrane to the exterior where PS serves as a putative “eat me” signal to enhance engulfment 
by phagocytes. PS can be recognized by TIM (T cell immunoglobulin and mucin domain 
containing protein)-4, a member of the TIM family primarily expressed on antigen presenting 
cells, where it can bind to PS exposed on the surface of apoptotic bodies to mediate their uptake 
(206, 207). TIM-4 deficient macrophages cannot phagocytose apoptotic cells both in vitro and in 
vivo (90, 164, 201). Moreover, TIM-4-deficient mice develop antibodies to double-stranded 
DNA, as well, hyperactive T and B cells responses (201). Similar to TIM-4, membrane tyrosine 
kinase c-mer (MERTK) is implicated in dead cell clearance and autoimmune pathology (207). 
Growth arrest specific protein-6 (GAS6) is reported to be a ligand for MERTK that can bind to 
PS, mediating its role in apoptotic removal (208). Clearance of exogenous apoptotic cells is 
delayed in mice missing the intracellular kinase domain of MERTK (C-Merkd). Merkd C57BL/6 
mice have a normal lifespan but do develop autoantibodies to DNA and mild renal disease (209).  
SLE associated loss of function polymorphisms in Milk fat globule-EGF factor 8 (MFG-
E8) further support a role for dead cell clearance in lupus (210). MFG-E8 is a glycoprotein 
abundantly expressed in lactating mammary glands and milk fat globules but also can be 
produced by macrophages where it can bind PS and mediate engulfment of dead cells via the 
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αvβ3 integrin (211). Mfg-e8−/− mice develop spontaneous autoimmunity characterized by the 
generation of anti-nuclear antibodies, splenomegaly, and glomerulonephritis (212). 
Concordantly, MFG-E8-deficient mice subjected to the pristane model of SLE develop more 
severe renal disease and diffuse alveolar hemorrhage (213). After pristane treatment Mfg-e8−/− 
mice have greater accumulation of apoptotic cells in the lung and peritoneum, a phenotype 
partially attributed to a failure to clear this debris (213). In this same study, MFG-E8 was 
elevated in the serum of lupus patients, a finding that needs to be reconciled. The authors 
postulate that high concentrations of MFG-E8 can inhibit engulfment of apoptotic cells (213).  
 CYBB is implicated in both cell death and subsequent clearance of debris by 
macrophages. CYBB deficiency is associated with SLE in both mouse and humans. The role of 
CYBB in SLE was discussed in chapter 3.    
Taken together, these studies emphasize that an inadequate clearance of dead cells can 
result in an immune response to self and end-organ damage. 
4.1.2 LC3-associated phagocytosis: A distinct process from canonical autophagy required 
for the clearance of dead cells 
Canonical autophagy refers to a catabolic cell survival process, triggered under nutrient scarce 
conditions, whereby the cell can degrade and recycle component (214, 215). This process 
requires the assembly of a preinitiation complex comprised of ULK1, FIP200, and ATG13 that is 
triggered under starvation conditions by AMPK and mTOR-mediated phosphorylation of 
ULK1 (214-216) (217). ULK1 phosphorylates BECLIN-1, a member of the Class III PI(3)K 
family, resulting in the translocation of this complex to the autophagosome where it can generate 
phosphatidylinositol 3-phosphate (PtdIns(3)P) and mediate the  activation of the ubiquitination-
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like protein conjugation system (214). The ubiquitination-like protein conjugation system is 
responsible for the lipidation of microtubule associated protein 1A/1B–light chain 3 (LC3), 
which can translocate to autophagosome membrane (214).  
LC3 associated phagocytosis (LAP) is a novel form of non-canonical autophagy 
implicated in the clearance and degradation of dead cells (164). LAP can occur in cell 
populations with phagocytic capacity including macrophages, dendritic cells, epithelial cells, and 
endothelial cells (218). Upon phagocytosis, cargo can be sensed by cell surface receptors, 
facilitating the recruitment of a subset of the autophagy machinery and subsequent conversion of 
LC3 to its lipidated form, LC3-II. LC-3II decorating the phagosomal membrane mediates 
lysosomal to phagosomal fusion and subsequent degradation of enclosed cargo (218). Several 
receptor classes are associated with the induction of LAP including: (1) pattern recognition 
receptors that recognize conserved moieties on pathogens, (2) immunoglobulin receptors that 
engage opsonized particles or cells, and (3) receptors that mediate dead cell clearance, such as, 
the TIM family (218). Strikingly, LAP can be induced in the context of MYD88 and TRIF 
deficiency, suggesting that these two critical adaptors, which are required for the signaling of all 
TLR family members are dispensable for LAP. The pathway that initiates LAP downstream of 
TLRs remains to be discovered (219).  
 There are several major distinctions between LAP and canonical autophagy. First, 
the phagosome associated with LAP or the “LAPosome” is a single membrane structure, while 
the autophagosome is enclosed by a double membrane (219). During LAP, the phagosome is 
fully sealed prior to the lipidation of LC3 and the ubiquitin conjugation system requisite for this 
process may still be attached to the membrane at its conclusion (219). However, LC3 is lipidated 
during autophagosome membrane elongation and the complex is released proximal to membrane 
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closure (220, 221).  Autophagy requires activation of the preinitiation complex, but LAP does 
not require the preinitiation complex for its initiation or progression (89, 164). LAP utilizes a 
variant of the BECLIN1-VPS34 complex that does not require ATG14 (89). LC3 lipidation in 
both LAP and canonical autophagy require utilization of the ubiquitin-like conjugation system 
comprised of ATG7, ATG3, ATG5, ATG12, and ATG16L (89). There are two molecules 
required for LAP but not canonical autophagy: CYBB and RUBICON, the RUN domain as 
BECLIN-1 interacting and cysteine-rich containing protein. CYBB operates downstream of the 
Class III PI(3)K complex, producing ROS requisite for the recruitment of the conjugation system 
(89). The function of Rubicon in LAP will be discussed in the next section.   
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4.1.3 RUBICON: Structure and function in the immune system 
RUBICON is a 972 amino acid (108.6 kDa) protein comprised of a RUN domain, an N-terminal 
serine-rich region (SR-N), a coiled-coil domain (CCD), a C-terminal serine- rich region (SR-C), 
a helix-coil-rich region (H-C), and a cysteine-rich region (C-R) (222). Studies report that 
RUBICON-GFP localizes to the late endosome/lysosome, though not to the autophagosome (89, 
222, 223). Rubicon is a member of the Class III PI(3)K complex and can bind BECLIN-1 at its 
CCD domain (222, 223). Multiple groups demonstrated that knockdown or genetic deletion of 
Rubicon increases the number of autophagosomes, identifying RUBICON as a negatively 
regulator of canonical autophagy (89, 222, 223). It is postulated that RUBICON blocks 
autophagy at the maturation step where the autophagosome fuses to the endosome/lysosome 
(222, 223). More recently, Martinez and colleagues reported that RUBICON is required for LAP, 
by associating with the LAPasome but not conventional phagosomes (89). RUBICON has 
opposing roles in regulating VPS34, the phosphatidylinositol 3-kinase in the Class III PI(3)K 
complex, during autophagy and LAP. While RUBICON reduces the activity of VPS34 during 
autophagy (222), it is required for VPS34 function during LAP sustaining PtdIns(3)P presence 
on the LAPosome (89). Therefore, RUBICON may not only serve as a negative regulator of 
autophagy but as a switch between these two related processes. 
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RUBICON is also important for the regulation of the NADPH oxidase complex by both 
direct and indirect mechanisms. Upon initiation of LAP, Rubicon activates the class III PI3K 
complex to generate PtdIns(3)P which is important for the recruitment of the soluble oxidase 
component p40phox (89). Additionally, Rubicon is reported to directly bind to p22phox, stabilizing 
the NADPH oxidase complex to facilitate its localization to the phagosome (89, 224). 
Intriguingly, BECLIN-1 and p22phox do not bind to the same region of RUBICON; BECLIN-1 
binds to the CCD domain while p22phox associates with the SRC region (224). Indeed, Rubicon-
deficient macrophages do not generate NADPH oxidase dependent ROS (89, 224).  
The role of RUBICON in the regulation of cytokine production and signaling remains 
controversial and could be context dependent. There are several lines of evidence to suggest that 
Rubicon negatively regulates cytokine production and signaling. In one study, RUBICON was 
implicated in mediating immune responses downstream of the CARD9 dependent pathways, 
RIG-I and Dectin-1(224). Under homeostatic conditions RUBICON binds 14-3-3β. However, 
upon engagement of CARD9-dependent pattern recognition receptors (PRR), RUBICON is 
phosphorylated and disassociates from 14-3-3β, allowing it to bind to CARD9 (224). 
Interestingly, CARD9 and 14-3-3β bind Rubicon at distinct domains, the H-C region and the SR-
N region respectively (224). This swap of binding partners leads to the disassembly of the 
CARD11-BCL10-MALT1 (CBM) signalosome complex and subsequent reduction of CBM 
dependent pro-inflammatory cytokine production (224). Recent reports suggest that RUBICON 
is a negative regulator of virus induced type I IFN signaling by binding IRF3 and preventing its 
dimerization (225). Discordant with these observations, shRNA mediated knockdown of 
RUBICON in bone marrow derived macrophages (BMDMs) and in RAW264.7 cells reduce 
proinflammatory cytokine production induced by zymosan, Listeria monocytogenes, and 
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Mycobacterium bovis BCG (224). Proinflammatory cytokine production requires Rubicon to 
associate with P22phox, indicating Rubicon is likely promoting proinflammatory cytokine 
production via stabilization and activation of the NADPH oxidase complex (224). More recently, 
it was reported that the anti-inflammatory response to apoptotic cell engulfment requires 
RUBICON and LAP (90). Rubicon-deficient macrophages generate proinflammatory cytokines 
in response to phagocytosis of apoptotic cells (90). Moreover, Rubicon-deficient mice have 
elevated levels of IL-1β, IL-6, IL-12p40, IP10 by 24 weeks of age (90). These discordant 
observations emphasize that the function of Rubicon in cytokine production is unclear and 
requires further investigation. 
RUBICON has divergent roles in host defense. Clearance of Aspergillus fumigatus is 
impaired in the context of Rubicon deficiency (89). The authors attribute this phenotype to a 
failure in LAP as genetic deletion of other LAP mediators recapitulated this finding (89). 
Similarly, in Listeria monocytogenes infection, shRNA-mediated knockdown of RUBICON in 
vivo was deleterious to the host, resulting in decreased proinflammatory cytokine production, 
increased pathogen burden, and decreased survival (224). However, knockdown of RUBICON in 
the setting of Candida albicans infection and influenza had the opposite effect and protected the 
host, increasing survival. In these contexts, proinflammatory cytokine production was elevated 
and pathogen burden reduced upon shRNA mediated knockdown of RUBICON in vivo (224). 
Taken together, the structure of RUBICON positions it to be a pleiotropic modulator of cytokine 
regulation able to adapt to the context of the pathogen assault.  
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4.1.4 LAP and autophagy in SLE 
Genetic variations of several components shared by LAP and canonical autophagy are associated 
with systemic autoimmunity in human patients and in mice. Genome wide association studies 
(GWAS) suggest that the PRDM1-ATG5 gene region is associated with SLE in both Caucasian 
and Chinese populations (226). Interestingly, one study suggested that the risk associated with 
ATG5 mutations is dependent on IL-10 genotype (227). SLE patients homozygous for the 
rs573775 (C to T) SNP in the ATG5 gene had higher levels of serum IL-10 but lower levels of 
IFNα (227). Further analysis revealed that the rs573775 T allele was only a risk factor for SLE 
in people who were also carriers of a polymorphism in IL-10 that conferred increased IL-10 
production (227). SLE patients who were concomitant high IL-10 producers and carriers of the 
rs573775 T allele had a significantly lower prevalence of cytopenia and a trend of reduced renal 
manifestations of disease (227). More recently, gain of function polymorphisms in LC3 were 
associated with SLE in Chinese populations. LC3 gene expression was increased in peripheral 
blood mononuclear cells (PBMCs) from SLE patients compared to healthy controls (208). 
Moreover, LC3-II protein was elevated in lymph nodes from MRL.Faslpr SLE prone mice (208). 
Recently, Martinez and colleagues showed that genetic deletion of components 
implicated in LAP only (Rubicon and Cybb) or LAP and canonical autophagy (Beclin1, Atg5, 
and Atg7) led to an autoinflammatory syndrome in non-autoimmune strains (90). LAP-deficient 
C57BL/6 mice spontaneously developed elevated titers of autoantibodies and renal disease (90). 
Interestingly, increased levels of proinflammatory cytokines were present in the serum of LAP-
deficient mice but anti-inflammatory cytokines, such as, IL-10 were reduced (90). The authors 
postulates that in the absence of LAP, dead cells are not cleared in an immunologically silent 
way as cell corpse degradation is impaired and that the inability to generate IL-10 downstream of 
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LAP is a major driver of the disease phenotype (90). However, one cannot exclude the 
possibility that an inability to degrade cell corpses could frustrate further clearance of dead cells, 
leading to the accumulation of self antigen. Strikingly, mice deficient in components only 
implicated in canonical autophagy (ULK1 and FIP200) did not develop systemic autoimmunity 
with age, suggesting that LAP but not canonical autophagy is required to prevent autoimmunity 
(90). 
4.1.5 IL-10 and SLE 
IL-10 is pleotropic cytokine that signals through a heterodimeric receptor composed of 
inducible IL-10R1 and constitutively expressed IL-10R2 (228). Upon receptor engagement, 
JAK1 and TYK2 are recruited to the IL-10 receptor where they can facilitate STAT3 
homo/hetero dimer activation and translocation to the nucleus where STATs can serve as 
transcription factors (228). IL-10 is expressed in most immune cells including T cells, B cells, 
NK cells, DCs, macrophages, and granulocytes (228). Multiple immunosuppressive mechanisms 
have been ascribed to IL-10 including repression of cell proliferation, suppression of 
proinflammatory cytokine production, reduction in antigen presentation and expression of co-
stimulatory molecules, and prevention of class switching by B cells (228).  
While IL-10 is generally thought to suppress the immune response, there are 
circumstances, especially in the context of inflammation, where it can take on pro-inflammatory 
properties.  One study suggests that IFNγ can reprogram IL-10 activity and signaling conferring 
proinflammatory function (229). This study reported that IFNγ switches the balance of IL-10 
STAT activation from STAT3 to STAT1, resulting in the expression of proinflammatory genes 
(229). Under these circumstances, IL-10 no longer prevents suppression of cytokine production 
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or reduction in MHCII expression (229). IL-10 was also suggested to increase proliferation and 
cytotoxic activity of CD8+ T cells and NK cells (230-232). In B cells, IL-10 has been shown to 
enhance MHCII expression, promote increased antibody secretion, and increase both survival 
and proliferation in vitro (233-236). However, these findings have not been confirmed in vivo.  
 The function of IL-10 in SLE and its cellular source remains an open question.  Gain of 
function polymorphisms in the IL-10 promoter are associated with SLE in European populations 
(237, 238). Elevated levels of IL-10 are observed in SLE patients and associated with disease 
activity (239). In this context, it is possible that increased IL-10 expression serves as a feedback 
mechanism to ameliorate rampant inflammation. Surprisingly, continuous administration of anti-
IL10 antibodies delayed onset of autoimmunity in the NZB/W F1 spontaneous mouse model of 
SLE (240). This observation was also recapitulated in a small study of human lupus patients. 
Here, anti-IL-10 administered to six human lupus patients with active disease led to a reduction 
in disease activity (241). These studies implicate IL-10 as pathogenic in lupus. 
 In contrast, some studies support a regulatory role of IL-10 in autoimmunity. IL-10 
deficient mice on a non-autoimmune background develop inflammatory bowel disease. Genetic 
deletion of IL-10 in the MRL.Faslpr model of SLE reduced survival and exacerbated renal 
manifestations of lupus (242). Supporting this finding, low dose overexpression of IL-10 in the 
spontaneous B6.Sle1.Sle2.Sle3 model, in which 3 SLE loci derived from the NZM2410 
autoimmune prone strain were crossed onto the C57BL/6 background, delayed the formation of 
autoantibodies and reduced the severity of renal disease (243). B cell-produced IL-10 has been 
implicated in autoimmune diseases including SLE (244). The role of B cell derived IL-10 in SLE 
was tested by our group using a Cre-lox approach to specifically knockout IL-10 in B cells in the 
MRL.Faslpr model (245). However, B cell-specific IL-10 deletion did not impact clinical or 
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immunological manifestations of SLE (245). To determine the cellular source of IL-10 in SLE, 
our group crossed MRL.Faslpr mice to the 10BiT reporter strain, where Thy-1.1 expressed under 
the control of an Il10 promoter marks cells that transcribe Il10 (245). This study revealed that T 
cells and macrophages are the primary IL-10 producers in SLE prone mice (245). As noted 
above, IL-10 is not produced upon the engulfment of dead cells by macrophages that have a 
defect in LAP. IL-10 production was suggested to be requisite for prevention of autoimmune 
manifestations in the setting of defective LAP (90). To date, the role of IL-10 in SLE remains 
controversial and requires further exploration.  
4.1.6 An approach to investigate whether Cybb deficiency exacerbates SLE by a defect in 
LAP 
While evidence suggests that blocking non-canonical autophagy can drive an anti-self response 
in a non-autoimmune setting, its role in SLE remains enigmatic. As NADPH oxidase is required 
for LAP, it is possible that the exacerbated disease observed in the context of Cybb deficiency is 
due to inhibition of this process. Here, we aimed to determine whether Cybb deficiency 
exacerbates SLE by prevention of dead cell clearance due to a defect in LAP and subsequent 
inhibition of anti-inflammatory cytokine production. We addressed this question by genetically 
deleting another requisite component for LAP, Rubicon, in the MRL.Faslpr lupus model. To 
determine whether CYBB and RUBICON act in the same pathway (ie LAP), we performed an in 
vivo complementation experiment, analyzing Cybb and Rubicon single and double knockout 
mice in the setting of lupus. Furthermore, we elucidated the function of IL-10 expressed in 
myeloid cell in SLE using a Cre-lox approach. 
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4.2 EVALUATION OF THE ROLE OF RUBICON IN SLE PATHOGENESIS 
To investigate the role of Rubicon in systemic autoimmunity, we generated a Rubicon-deficient 
mouse on the MRL.Faslpr background using CRISPR-Cas9 technology. Heterozygous knockout 
mice were intercrossed to produce an experimental cohort. SLE pathology was analyzed at 17 
weeks of age. If Cybb deficiency promotes lupus by a defect in LAP, we expect that Rubicon-/- 
and Rubicon-/- Cybb-/- MRL.Faslpr mice to develop exacerbated manifestations of SLE. 
4.2.1 Generation of the Rubicon-/- on the MRL.Faslpr background using CRISPR-Cas9 
The Rubicon knockout allele was generated directly on the MRL.Faslpr background using in vitro 
fertilization coupled with CRISPR-Cas9 technology as previously described and detailed in the 
materials and methods (Figure 41A) (89, 185). In brief, a premature stop codon replacing 
Asp188 was introduced in exon 5 of the Rubicon gene by homology directed repair following 
injection of in vitro generated MRL.Faslpr pronuclear-stage zygotes with capped Cas9 mRNA, a 
sgRNA targeting the end of exon 5, and a 183-nucleotide-long ssODN that served as a repair 
template. To facilitate screening of founder mice, an EcoRI restriction site was introduced 
adjacent to the stop codon. 42% of the mice born had at least one sequence confirmed copy of 
the integrated repair construct at the cut site (Figure 41B). We confirmed that RUBICON protein 
was absent in the spleens and bone marrow of Rubicon-deficient mice (Figure 41C).  
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4.2.2 Rubicon deficiency reduced SLE renal disease in MRL.Faslpr mice 
Rubicon-deficient male and female MRL.Faslpr mice have reduced urine protein compared to 
wild-type controls (Figure 42A). No differences in dermatitis were identified amongst the groups 
(Figure 42B). While Rubicon genotype did not alter glomerulonephritis (Figure 42C) in 
MRL.Faslpr mice, interstitial nephritis was ameliorated in Rubicon-/- males with a trend towards 
reduction in females (Figure 42C). Spleen weight was decreased in in Rubicon-/- male and female 
lupus-prone mice (Figure 43A). However, no differences in lymphadenopathy were observed 
across the groups (Figure 43B). 
4.2.3 RUBICON regulates the anti-RNA and anti-Sm response 
Rubicon deficiency reduced anti-RNA titers in both male and female MRL.Faslpr mice (Figure 
44A). Strikingly, anti-Sm autoantibodies were absent from male Rubicon-/- MRL.Faslpr mice 
(Figure 44B and C). Only one out of 19 female Rubicon-/- MRL.Faslpr mice had positive anti-Sm 
titer (Figure 44B and D). Intriguingly, no differences in anti-nucleosome (Figure 44E) or RF 
(Figure 44F) titers were identified between the groups. 
4.2.4 The percentages of plasmablasts were decreased in Rubicon-/- MRL.Faslpr mice 
Rubicon-deficient mice did not have any changes to the percentage of CD19+ B cells in 
comparison to wild-type mice (Figure 44G). However, CD19low-int CD44+ CD138+ intracellular 
κhigh AFCs were reduced in Rubicon-deficient male and female MRL.Faslpr cohorts compared to 
controls (Figure 44H).  
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4.2.5 Rubicon deficiency did not impact the myeloid compartment in SLE prone mice 
Rubicon genotype had only a minor impact on the myeloid compartment in MRL.Faslpr mice. 
The percentages of CD11b+Ly6G+ splenic neutrophils (Figure 45A) and CD11b+F4/80+Gr1low-int 
splenic macrophages (Figure 45B) were not statistically different across Rubicon genotype. 
Rubicon-deficient MRL.Faslpr females had a greater percentage of CD19-CD11c+MHCII+ cDCs 
(Figure 45C). Additionally, male Rubicon-/- MRL.Faslpr mice had a lower percentage of CD19-
BST2+ SiglecH+ pDCs (Figure 45D) compared to Rubicon-sufficient controls. 
4.2.6 RUBICON did not alter the T cell compartment in MRL.Faslpr mice 
Rubicon deficiency did not substantially impact the lymphoid compartment. All genotypes 
exhibited indistinguishable total percentages of TCRβ+ T cells (Figure 46A). The percentages of 
CD4+ T cells and CD4+CD44+CD62L- activated T cells were also not significantly different 
across all groups (Figure 46B). Similar results were obtained for naive and activated CD8+ T 
cells (Figure 46C).  
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Figure 41. Generation of the Rubicon knockout mouse on the MRL.Faslpr background using CRISPR-Cas9 
and in vitro fertilization. 
(A) CRISPR-Cas9 strategy to generate the Rubicon knockout allele. (B) Sequencing chromatogram depicting the 
stop codon in the Rubicon-knockout MRL.Faslpr founder (C) Western blot analysis of spleen and bone marrow from 
Rubicon+/+, Rubicon+/-, and Rubicon-/- MRL.Faslpr mice.  
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Figure 42. Rubicon deficiency reduced SLE renal disease in MRL.Faslpr mice. 
(A) Proteinuria. (B) Dermatitis.  (C) Glomerulonephritis scores. (D) Interstitial nephritis scores. (E) Spleen Weight. 
(F) Axillary lymph node weights. Scores and weights are represented as a function of Rubicon-genotype and gender 
at 18 weeks of age. Bars represent the median and each dot represents and individual mouse. A Mann-Whitney U 
test was performed to determine statistical significance within each gender (* indicates p≤0.05, ** p≤0.01, *** 
p≤0.001, and **** p≤0.0001; n=8 to 29 mice per group; ⊗ and  denote deceased animals). 
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Figure 43. Decreased spleen and lymph nodes weights in Rubicon-deficient SLE prone mice. 
(A) Spleen weight. (B) Axillary lymph node weights. Data representation, and statistics are as in Figure 42. 
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Figure 44. Rubicon deficiency altered the anti-self response in MRL.Faslpr mice. 
(A and B) Serum anti-RNA (A), anti-Sm (B) titers. (C and D) Number of male (C) and female (D) mice with 
positive anti-Sm titers. The dotted line in B represents the positive threshold. (E and F) Serum anti-nucleosome 
antibody (E) and rheumatoid factor titers (E).  (G) Percentages of live CD19+ total B cells. (H) Percentages of live 
cells that are TCRβ− CD44+ CD138+ intracellular κ+ antibody forming cells. FCs. Data representation, number of 
mice, and statistics are as in Figure 42. In panels E and F, bar graphs are represented as the mean ± SEM and a two- 
tailed Welch’s T test was performed to determine statistical significance within each gender. In panels C and D, a 
Fisher’s exact test was used to determine statistical significance (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and 
**** p≤0.0001; n=8 to 20 mice per group).   
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Figure 45. The composition of the myeloid compartment was not altered in Rubicon-deficient mice  
 (A) Percentages of live CD11b+ Ly6G+ neutrophils in the spleen. (B) Percentages of splenic CD11b+ GR1low-int 
F4/80+ macrophages. (C) Percentages of live CD19- MHCII+ CD11c+ conventional dendritic cells and (D) CD19- 
BST2+ CD11c+ plasmacytoid dendritic cells. Bar graphs are represented as the mean ± SEM and a two-tailed 
Welch’s T test was performed to determine statistical significance within each gender (* indicates p≤0.05, ** 
p≤0.01, *** p≤0.001, and **** p≤0.0001; n=8 to 20 mice per group).   
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Figure 46. Rubicon deficiency did not alter the T cell compartment in lupus prone mice. 
(A) Percentages of live TCRβ+ total T cells. (B) Percentages of live TCRβ+ CD4+ T cells (left panel) and of CD4+ 
CD44+ CD62L- activated T cells (right panel). (C) Percentages of live TCRβ+ CD8+ T cells (left panel) and of CD8+ 
CD44+ CD62L- activated T cells (right panel). Data representation, number of mice, and statistics are as in Figure 
45. 
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4.3 CHARACTERIZATION OF RUBICON IN THE SETTING OF CYBB 
DEFICIENCY IN SLE 
Given the reported interplay between RUBICON and CYBB and their role in LAP, we sought to 
determine how Rubicon-deficiency modulates disease in the context of Cybb genetic deletion. 
We generated cohorts of Rubicon and Cybb single and double knockouts by performing the 
following crosses: 1. Rubicon+/- Cybby/- X Rubicon+/-Cybb+/-, 2. Rubicon+/- Cybby/+ X Rubicon+/-
Cybb+/-, and 3. Rubicon+/- Cybby/+ X Rubicon+/-Cybb+/+. SLE pathology was analyzed at 17-18 
weeks of age. Autoimmune-prone mice with a global defect in NADPH oxidase prematurely 
succumb to renal failure as the primary cause of death. This was again observed in our cohort. 
We nonetheless allowed the cohort to age to 17-18 weeks to better assess the effects of 
concomitant Rubicon deficiency. In order to prevent the deaths of Cybb-/- mice from artificially 
skewing the scores for kidney disease, we assigned these subjects the second highest proteinuria, 
glomerulonephritis and interstitial nephritis scores. 
4.3.1 Rubicon deficiency reduced mortality in Cybb-deficient MRL.Faslpr mice 
Consistent with the prior literature, in our cohort, the male and female Cybb-deficient 
MRL.Faslpr mice had a reduced lifespan compared to Cybb-sufficient controls. 50% or more of 
the experimental Cybb-/- cohort did not survive until the experimental endpoint of 17 weeks 
(Figure 47). Surprisingly, Rubicon-deficiency did not recapitulate the phenotype observed in the 
Cybb-/- MRL.Faslpr mice as no Rubicon-deficient mice died in the analyzed cohorts (Figure 47).  
Strikingly, Rubicon deficiency increased survival in male Cybb-/- and trended towards protection 
in female MRL.Faslpr mice (Figure 47; bottom panel).  
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4.3.2 Rubicon deficiency protected Cybb-/- SLE prone mice from exacerbated renal 
disease. 
Genetic deletion of Rubicon reduced proteinuria in male and female Cybb-deficient SLE prone 
mice (Figure 48A). No differences in dermatitis were observed in either group (Figure 48B). 
Concordant with the proteinuria data, Rubicon-deficiency reduced both glomerulonephritis 
(Figure 48C and E) and interstitial nephritis (Figure 48D and E) in Cybb-deficient male and 
female MRL.Faslpr mice. Rubicon deficiency reduced spleen weight in Cybb-/- male mice 
MRL.Faslpr mice (Figure 49A). No changes in axillary lymph node weights were found (Figure 
49B).  
4.3.3 Rubicon deficiency abrogates the anti-Sm responses in Cybb-deficient MRL.Faslpr 
mice 
We previously showed that Cybb deficiency increases the anti-RNA and anti-Sm response in 
SLE prone mice. Discordant with these observations Rubicon-/- mice have reduced responses to 
RNA and Sm antigen. We identify a trend towards decreased anti-RNA titers in male Rubicon-/-
Cybb-/- MRL.Faslpr mice (Figure 50A). Strikingly, Rubicon deficiency abolishes the anti-Sm 
response in male Cybb-/- lupus prone mice (Figure 50B and C). Similar to what we observed in 
the male cohort, only 1/7 female Rubicon-/-Cybb-/- female MRL.Faslpr mice had positive Anti-Sm 
titers (Figure 50B and D). No differences in anti-nucleosome (Figure 50E) or RF (Figure 50F) 
titers were identified between the Cybb-/- and Rubicon-/-Cybb-/- cohorts. While no changes in the 
percentage of total CD19+ B cells (Figure 50G) was observed between groups, male Rubicon-/-
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Cybb-/- did have reduced CD19low-int CD44+ CD138+ intracellular κhigh AFCs (Figure 50H) 
compared to Cybb-/- SLE prone mice.  
4.3.4 Rubicon deficiency decreased splenic macrophage expansion in female Cybb-/- SLE 
prone mice 
Others and we have previously reported that global and hematopoietic NADPH oxidase 
deficiency leads to an expansion of the myeloid compartment in both autoimmune and non-
autoimmune mouse strains (75, 82, 137). Rubicon genotype had only a minor impact on the 
myeloid compartment in Cybb-deficient MRL.Faslpr mice. All genotypes exhibited similar 
frequencies of CD11b+Ly6G+ splenic neutrophils (Figure 51A) among the groups. Interestingly, 
Rubicon deficiency reduced the percentage of macrophages in female Rubicon-/-Cybb-/- mice 
(Figure 51B). We did not identify and differences in the total percentage of splenic cDCs (Figure 
51C) and pDCs (Figure 51D) between the groups.   
4.3.5 RUBICON has a minimal impact on the T cell response in Cybb-deficient 
MRL.Faslpr mice 
Rubicon deficiency did not alter the lymphoid compartment in Cybb-/- SLE prone mice. No 
statistically significant differences in the total percentage of TCRβ+ T cells (Figure 52A) were 
observed. The percentages of CD4+ T cells and CD4+CD44+CD62L- activated T cells were also 
not divergent across all groups (Figure 52B). Similarly, no change in the percentage of naive and 
activated CD8+ T cells was identified between Cybb-/- and Rubicon-/-Cybb-/- SLE prone mice 
(Figure 52C).  
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4.3.6 Peritoneal and bone marrow derived macrophages derived from Rubicon- and 
Cybb-deficient mice lipidate LC3 in response to zymosan bioparticles 
Previous literature implicated RUBICON and CYBB as required for LAP and that “LAP”-
deficient mice on a non-autoimmune background develop a SLE-like disease (89, 90). To 
confirm that LAP does not occur in Cybb and Rubicon-deficient macrophages, we generated 
BMDMs from 6-8 week old Cybb-/- and Rubicon-/- MRL.Faslpr mice and stimulated them with 
zymosan bioparticles to initiate LAP. Upon the induction of LAP, LC3 is converted to its 
lipidated form, LC3-II on the LAPasome membrane. This step is reported to be downstream of, 
and hence require, both NADPH oxidase and RUBICON. To our surprise, both Cybb and 
Rubicon-deficient BMDMs could lipidate LC3, a surrogate readout for LAP (Figure 53 A). 
These findings were recapitulated in peritoneal macrophages isolated from young Pre-
autoimmune (6-8 week old) Cybb-/- and Rubicon-/- MRL.Faslpr mice (Figure 53A). Reports 
suggest that LC3 is elevated in autoimmune patients and in autoimmune mouse strains at disease 
endpoints. To further investigate this, we stimulated peritoneal macrophages isolated from 18 
week old wild-type, Cybb-/-, Rubicon-/-, and Cybb-/- Rubicon-/- MRL.Faslpr mice (Figure 53B). We 
did not observe consistent increased protein expression of LC3 at baseline. Again, zymosan 
stimulation led to the lipidation of LC3 in all conditions. It was possible that strain differences 
alter the requirements for CYBB and RUBICON in LAP, as the original observations that LAP 
was dependent on NADPH oxidase and Rubicon were made in C57BL/6 mice. To address this 
issue, we stimulated BMDMs from Cybb-/- C57BL/6 mice with zymosan bioparticles. Similar to 
the situation in MRL.Faslpr mice, LC3 was lipidated under these conditions (Figure 53C) in cells 
derived from C57BL/6 mice. Of note, we used rapamycin and starvation to induce canonical 
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autophagy as a positive control. In our hands, these conditions led to only some weak and 
variable LC3 lipidation, which we attribute to significant cell death observed in these cultures.  
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Figure 47. Rubicon deficiency conferred a survival advantage in Cybb-deficient MRL.Faslpr mice. 
Kaplan-Meir survival curves of the following comparisons: wild-type vs. Cybb-/- (top panel), Cybb-/- vs. Rubicon-/- 
(middle panel), and Cybb-/- vs. Cybb-/-Rubicon-/- (lower panel). Data are segregated by gender with males on the left 
and females on right. A log rank test was used to determine statistical significance (* indicates p≤0.05, ** p≤0.01, 
*** p≤0.001, and **** p≤0.0001; n=8 to 23 mice per group).   
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Figure 48. Rubicon deletion decreases exacerbated renal disease in Cybb-deficient MRL.Faslpr mice. 
(A) Proteinuria. (B) Dermatitis.  (C) Glomerulonephritis scores. (D) Interstitial nephritis scores. (E) Representative 
images of H&E-stained kidney sections showing glomeruli and interstitial infiltrates from wild-type (top left), 
Rubicon-/- (top right), Cybb-/- (bottom left), and Rubicon-/-Cybb-/- (bottom right) MRL.Faslpr mice. Scores are 
represented as a function of Rubicon- and Cybb-genotype and gender at 18 weeks of age. Bars represent the median 
and each dot represents and individual mouse. A two-tailed Mann-Whitney U test was performed to determine 
statistical significance within each gender (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=7 to 
29 mice per group; ⊗ and  denote deceased animals). 
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Figure 49. Decreased spleen weight in Rubicon-/-Cybb-/- SLE prone mice. 
(A) Spleen weight. (B) Axillary lymph node weights. Data representation, number of mice, and statistics are as in 
Figure 48. 
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Figure 50. Rubicon deficiency abrogates the anti-Sm responses in Cybb-deficient MRL.Faslpr mice 
(A and B) Serum anti-RNA (A), anti-Sm (B) titers at 18 weeks of age. (C and D) Number of male (C) and female 
(D) mice with positive anti-SM titers. The dotted line in B represents the positive threshold. (E and F) Serum anti-
nucleosome antibody (E) and rheumatoid factor titers (E) at 18 weeks of age (G) Percentages of live CD19+ total B 
cells. (H) Percentages of live cells that are TCRβ− CD44+ CD138+ intracellular κ+ antibody forming cells. Data 
representation and statistics are as in Figure 48 (n=5 to 15 mice per group). In panels E and F, bar graphs are 
represented as the mean ± SEM and two-tailed Welch’s T test was performed to determine statistical significance 
within each gender. In panels C and D, a Fisher’s exact test was used to determine statistical significance (* 
indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** p≤0.0001; n=5 to 14 mice per group).   
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Figure 51. Rubicon deletion decreased splenic macrophage expansion in female Cybb-deficient SLE prone 
mice. 
(A) Percentages of live CD11b+ Ly6G+ neutrophils in the spleen. (B) Percentages of splenic CD11b+ GR1low-int 
F4/80+ macrophages. (C) Percentages of live CD19- MHCII+ CD11c+ conventional dendritic cells and (D) CD19- 
BST2+ CD11c+ plasmacytoid dendritic cells. Bar graphs are represented as the mean ± SEM and a two-tailed 
Welch’s T test was performed to determine statistical significance within each gender (* indicates p≤0.05, ** 
p≤0.01, *** p≤0.001, and **** p≤0.0001; n=5 to 14 mice per group). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
 
Figure 52. Rubicon deficiency did not alter the T cell compartment in Cybb-deficient MRL.Faslpr mice. 
(A) Percentages of live TCRβ+ total T cells. (B) Percentages of live TCRβ+ CD4+ T cells (left panel) and of CD4+ 
CD44+ CD62L- activated T cells (right panel). (C) Percentages of live TCRβ+ CD8+ T cells (left panel) and of CD8+ 
CD44+ CD62L- activated T cells (right panel). Data representation, number of mice, and statistics are as in Figure 
51. 
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Figure 53. Zymosan bioparticles induced the lipidation of LC3 in Rubicon- and Cybb-deficient macrophages. 
Peritoneal macrophages or bone marrow derived macrophages (BMDMs) were subjected to starvation conditions 
(EBSS) or stimulated with Rapamycin (200nm) for 6 or 18 hours as indicated. LC3-associated phagocytosis was 
induced by feeding zymosan bioparticles (8:1 (particles/cell)) to macrophages for 6 to 18 hours as indicated. Total 
cell lysates were resolved using SDS-PAGE and blotted with the indicated antibodies. (A) Peritoneal macrophages 
(left) or BMDMs (right) derived from pre-diseased 8 week old wild-type, Cybb-/-, or Rubicon-/- MRL.Faslpr mice. (B) 
Peritoneal macrophages isolated from 18 week old autoimmune wild-type, Cybb-/-, or Rubicon-/- , Rubicon-/- Cybb-/-, 
MRL.Faslpr mice. (C) BMDMs derived from 8 week old C57BL/6 Cybb-/- mice. 
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4.4 ANALYSIS OF MYELOID IL-10 DEFICIENCY IN SLE 
To assess the role of myeloid IL-10 deficiency in SLE, we backcrossed the IL-10fl/fl and LysM-
Cre alleles on to the MRL.Faslpr background for 10 generations. The fully backcrossed IL-10fl/fl 
and LysM-Cre MRL.Faslpr strains were intercrossed two generations to make the IL-10fl/fl allele 
homozygous. Resulting IL-10fl/fl LysM Cre+/- and IL-10fl/fl LysM Cre+/- were intercrossed to 
generate experiment cohorts. In this experiment, IL-10 should be deleted in neutrophils and 
macrophages of IL-10fl/fl LysM Cre+/- (LysM ∆IL-10) mice. SLE pathology was analyzed at 17 
weeks of age.  
4.4.1 LysM Cre efficiently deleted IL-10 in neutrophils but only partial deletion occurs in 
macrophages 
IL-10 deletion was measured by qPCR of genomic DNA acquired from FACS sorted immune 
cell populations. IL-10 was efficiently deleted in splenic CD11b+Gr1+ neutrophils isolated from 
IL-10flf/fl LysM-Cre+/- mice (77.67% ±0.67; Figure 54). Paralleling our prior observation, IL-10 
deletion in IL-10flf/fl LysM-Cre+/- CD11b+F4-80+ splenic macrophages was 43.48% (± 2.62; 
Figure 54). As expected, IL-10 deletion in CD19+ B cells was below the limit of detection 
(Figure 54).  
4.4.2 Renal disease was not impacted by myeloid IL-10 deficiency in SLE prone mice 
No differences in urine protein were detected in in SLE prone mice with a myeloid IL-10 defect. 
(Figure 55A). The incidence of dermatitis was not different across the groups (Figure 55B). We 
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did not observe differences in the severity of glomerulonephritis (Figure 55C) or interstitial 
nephritis (Figure 55D) in IL-10fl/fl LysM Cre+/- MRL.Faslpr mice compared to myeloid IL-10 
sufficient controls. No statistically significant differences in splenomegaly (Figure 55E) and 
lymphadenopathy were observed (Figure 55F).  
4.4.3 Myeloid IL-10 deficiency did not fundamentally alter the anti-self response 
Myeloid IL-10 genotype did not substantially alter the autoantibody response, with two notable 
exceptions. We did not detect any differences in anti-RNA antibody (Figure 56A) or anti-
nucleosome antibody (Figure 56C) titers. Female IL-10fl/fl LysM Cre+/- MRL.Faslpr had lower 
anti-Sm titers than IL-10-sufficient controls (Figure 56B). Male myeloid IL-10-deficient mice 
had increased titers of RF (Figure 56D). We did not detect any change in the percentage of total 
CD19+ B cells or CD19low-int CD44+ CD138+ intracellular κhigh AFCs across groups (Figure 56E 
and F). 
4.4.4 Myeloid IL-10 deficiency had no impact on the composition of the myeloid 
compartment 
Myeloid IL-10-genotype did not alter the percentage of CD11b+Ly6G+ splenic neutrophils 
(Figure 57A) or CD11b+F4/80+Gr1low-int splenic macrophages (Figure 57B). Similarly, no 
differences in the percentage of splenic CD19-CD11c+MHCII+ cDCs (Figure 57C) and CD19-
BST2+ SiglecH+ pDCs (Figure 57D) were identified among the groups. 
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4.4.5 Myeloid IL-10 deficiency had no impact on the T cell compartment 
The composition of the T cell compartment was not substantially impacted by myeloid IL-10-
deficiency in SLE prone mice. All genotypes exhibited indistinguishable total percentages of 
TCRβ+ T cells (Figure 58A). The percentages of CD4+ T cells and CD4+CD44+CD62L- activated 
T cells were not statistically different between IL-10fl/fl LysM Cre+/- and controls (Figure 58B). 
Analogous findings were observed for naive and activated CD8+ T cells (Figure 58C). 
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Figure 54.  LysM Cre efficiently deleted IL-10 in neutrophils but only partial deletion occurred in 
macrophages. 
Cybb deletion efficiency was quantitated by qPCR of genomic DNA isolated from FACS sorted splenic neutrophil, 
macrophages, and B cells. 
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Figure 55. Myeloid IL-10 deficiency did not impact renal disease in SLE prone mice. 
(A) Proteinuria. (B) Dermatitis.  (C) Glomerulonephritis scores. (D) Interstitial nephritis scores. (E) Spleen weight. 
(F) Axillary lymph node weights. Scores are represented as a function of IL-10fl/fl and LysM Cre genotype and 
gender at 18 weeks of age. Bars represent the median and each dot represents and individual mouse. A Mann 
Whitney U test was performed to determine statistical significance within each gender (* indicates p≤0.05, ** 
p≤0.01, *** p≤0.001, and **** p≤0.0001; n=13 to 34 mice per group). 
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Figure 56. The anti-self response was not altered in LysM ∆IL-10 MRL.Faslpr mice. 
(A-D) Serum anti-RNA (A), anti-Sm (B), anti-nucleosome antibody (C) and rheumatoid factor titers (D) at 18 weeks 
of age. (E) Percentages of live CD19+ total B cells. (F) Percentages of live cells that are TCRβ− CD44+ CD138+ 
intracellular κ+ antibody forming cells. Data representation, number of mice, and statistics are as in Figure 55. In 
panels E and F, bar graphs are represented as the mean ± SEM and a two-tailed Welch’s T test was performed to 
determine statistical significance within each gender. (* indicates p≤0.05, ** p≤0.01, *** p≤0.001, and **** 
p≤0.0001; n=13 to 31 mice per group).   
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Figure 57. Myeloid IL-10 deficiency did not change the composition of the myeloid compartment in SLE 
prone mice.  
(A) Percentages of live CD11b+ Ly6G+ neutrophils in the spleen. (B) Percentages of splenic CD11b+ GR1low-int 
F4/80+ macrophages. (C) Percentages of live CD19- MHCII+ CD11c+ conventional dendritic cells and (D) CD19- 
BST2+ CD11c+ plasmacytoid dendritic cells. Bar graphs are represented as the mean ± SEM and a two tail Welch’s 
T test was performed to determine statistical significance within each gender (* indicates p≤0.05, ** p≤0.01, *** 
p≤0.001, and **** p≤0.0001; n=13 to 31 mice per group).   
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Figure 58. The T cell compartment was not impacted by myeloid IL-10 deletion in MRL.Faslpr mice. 
(A) Percentages of live TCRβ+ total T cells. (B) Percentages of live TCRβ+ CD4+ T cells (left panel) and of CD4+ 
CD44+ CD62L- activated T cells (right panel). (C) Percentages of live TCRβ+ CD8+ T cells (left panel) and of CD8+ 
CD44+ CD62L- activated T cells (right panel). Data representation, number of mice, and statistics are as in Figure 
57. 
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4.5 DISCUSSION 
NADPH oxidase-deficient SLE prone mice develop exacerbated manifestations of SLE and die 
prematurely as a result of their disease (75, 76, 137). It has been postulated that NADPH oxidase 
dysfunction augments SLE by inhibiting LAP and the consequent immunologically silent 
degradation of dead cells. Rubicon and Cybb-deficient C57BL/6 mice develop a lupus like 
disease attributed to a defect in LAP (90). If these hypotheses were correct, genetic deletion of 
Rubicon, a required mediator for LAP, should phenocopy Cybb-deficiency in SLE prone mice. 
To address this question, we generated the Rubicon knockout mouse directly on the MRL.Faslpr 
SLE prone background. Unexpectedly, Rubicon-deficient MRL.Faslpr did not develop worsened 
clinical or immunological manifestations of SLE, as is the case for Cybb-deficient MRL.Faslpr 
mice. In fact, Rubicon deletion increases survival and ameliorates both glomerulonephritis and 
interstitial nephritis in Cybb-/- SLE prone mice. Production of IL-10 downstream of dead cell 
engulfment is thought to be a primary mechanism by which LAP protects against the immune 
response to self. Additionally, our group and others have identified macrophages as major 
producers of IL-10 in murine and human lupus. To determine the role of myeloid IL-10 in the in 
vivo disease setting, we genetically deleted IL-10 in neutrophils and macrophages in SLE prone 
mice by a Cre-lox approach, crossing the IL-10-floxed allele with LysM-Cre. The LysM Cre 
allele has been previously used to conditionally knockout LAP mediators in macrophages 
resulting the development of a spontaneous SLE-like disease. In contrast to this observation, 
myeloid IL-10 deletion did not alter SLE pathogenesis in the MRL.Faslpr model, suggesting that 
IL-10 production downstream of LAP is not a major regulatory mechanism augmenting systemic 
autoimmunity. Our complementation study demonstrates that exacerbated SLE in Cybb-deficient 
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mice is not a result of defective LAP. Taken together, the genetic studies we present here fail to 
support a role for defective LAP in driving SLE pathogenesis. 
Martinez and colleagues implicated RUBICON and CYBB as essential for LAP (89). To 
confirm that Rubicon-/- and Cybb-/- MRL.Faslpr macrophages were deficient in LAP, we 
stimulated BMDMs with the canonical LAP inducer, zymosan coated beads. Upon LAP 
initiation, LC3-I is lipidated to form LC3-II and translocates to the LAPsome membrane. We 
measured LC3-II as a molecular readout for the initiation of LAP. To our surprise, zymosan 
bioparticles induced the lipidation of LC3-I to form LC3-II in macrophages from both young 
pre-diseased and aged Rubicon-/, Cybb-/-, and Rubicon-/-Cybb-/ MRL.Faslpr mice. Moreover, we 
did not observe consistent elevated expression of either LC3-I or LC3-II in macrophages from 
diseased animals, discordant with previous observations reporting elevated LC3 protein in the 
lymph nodes of autoimmune MRL.Faslpr mice (228). It is conceivable that the MRL background, 
or the lpr mutation in the Fas gene that serves as disease accelerator, alters the requirements for 
CYBB and RUBICON in LAP. To address this concern, we repeated these studies in BMDMs 
generated from Cybb-/- C57BL/6 mice. We found that Cybb-/- C57BL/6 BMDMs do form LC3-II 
in response to zymosan coated beads, contrary to expectations. Importantly, the time points used 
in our study were different from those used by Martinez et al., as we assessed LC3 at 6 hours or 
18 hours post stimulation while they did so at 1 hour. It is possible that zymosan coated beads 
are inducing canonical autophagy, accounting for the increase in LC-II observed in our hands. To 
further address this issue, we will conduct experiments at shorter time point and we will confirm 
the localization of LC3 to the LAPasome by confocal microscopy. These studies will also be 
repeated in macrophages derived from mice with genetic deletions in the components of the pre-
initiation complex, requisite for canonical autophagy but dispensable for LAP. Taken together, 
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our studies highlight a potential flaw with the current view of the proteins required for LAP. 
Importantly, our work indicates that Rubicon may be working through a LAP-independent 
mechanism to augment SLE pathogenesis.  
Recently, RUBICON has been ascribed several immune regulatory functions, 
independent of LAP. Rubicon is reported to reduce CARD9 dependent cytokine signaling (224). 
In the context of viral infection, RUBICON can inhibit type I IFN responses by preventing IRF3 
dimerization (225). Based on these findings, it would be unexpected that Rubicon-deficiency is 
protective in the MRL.Faslpr model. Interestingly, data from our lab showed that IRF3 deficiency 
did not impact SLE pathogenesis in an F2 cohort. We also showed that, while genetic deletion of 
CARD9 reduces splenic myeloid expansion and reduces AFCs, it does not have any impact on 
proteinuria (F2 and fully backcrossed cohorts) or histological kidney disease (F2 cohort) 
(unpublished). Thus, neither IRF3 nor CARD9 pathways are likely to be major disease drivers, 
and therefore, the phenotype that we observe in Rubicon-deficient mice is inconsistent with the 
role of Rubicon in modulating CARD9 and IRF3 pathways.  
RUBICON can bind p22phox, stabilizing the NAPDH oxidase complex, requisite for 
NADPH oxidase dependent proinflammatory cytokine production (224). It is possible that in the 
absence of RUBICON, NADPH oxidase mediated proinflammatory cytokine production is 
reduced in MRL.Faslpr mice. This explanation is incongruent with our findings, as Cybb-/- 
MRL.Faslpr mice, without a functional active NADPH oxidase complex, develop exacerbated 
SLE. In the setting of Cybb-deficiency, it is possible that compensatory upregulation of another 
NOX complex (e.g. NOX1) could restore NADPH oxidase function. However, as others and we 
have shown, genetically deleting Cybb or cytosolic components of the NADPH oxidase complex 
all lead to exacerbated SLE in murine models. Hence, such a postulated compensatory 
 152 
mechanism would have to uniquely rely on the ability of RUBICON to upregulate NOX family 
members. As Rubicon-deficient mice cannot generate ROS, this explanation seems unlikely (89).  
Rubicon deficiency regulates the formation of antibodies towards RNA and 
ribonucleoproteins but not to DNA. We have previously reported that Cybb-deficient MRL.Faslpr 
mice develop elevated anti-RNA and anti-Sm titers (75). Impressively, Rubicon deletion 
abrogates the anti-Sm response in both Cybb-sufficient and -deficient SLE prone mice. This 
phenotype resembles the autoantibody response observed in Tlr7-/- MRL.Faslpr mice. Tlr7-/- 
MRL.Faslpr do not produce antibodies towards RNA and ribonucleoprotein but retain their ability 
to generate antibodies to DNA and chromatin (2, 3). Similar to Rubicon-deficient SLE prone 
mice, TLR7-/- MRL.Faslpr mice are protected from renal manifestations of SLE  (2, 3). To 
address whether Rubicon regulates TLR7 expression, we assessed TLR7 protein levels on total 
splenocytes by flow cytometry. We did not find any substantial differences in TLR7 protein 
expression in total B cells or the myeloid compartment (data not shown). These preliminary 
expression studies do not preclude Rubicon from altering TLR7 expression in specific B cell 
subsets. Furthermore, TLR7 and Rubicon both localize to the endosome and it is plausible that 
Rubicon could regulate TLR7 trafficking or signaling in B cells (89, 222, 223, 246). The 
interplay between Rubicon and TLR7 remains to be explored and is an active area of 
investigation by our laboratory.  
RNA must traffic to the endosome to be detected by endosomal TLR receptors, such as 
TLR7. One mechanism by which Rubicon could modulate SLE pathogenesis is through 
trafficking of RNA cargo. Indeed, ATG5, an E3 ligase required for both autophagy and LAP, has 
been implicated in RNA trafficking to TLR containing endosomes in DCs (247). A similar 
mechanism could deliver RNA cargo to endosomal TLR7s in B cells with significant 
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implications for the development of TLR7-dependent antibodies in SLE. Supporting this idea, B-
cell specific deletion of Atg5, improves both survival renal disease in the TLR7 transgenic model 
(TLR7.1 Tg) of SLE (248). The role of Rubicon in RNA trafficking and how that relates to SLE 
pathogenesis is intriguing and worthy of further study.  
The Rubicon knockout allele generated in this study is likely a true knockout and does 
not produce a dominant negative product.  We inserted a stop codon at position Asp188, located 
at the end of the RUN domain. The stop codon is situated upstream of regions known to code 
protein domains that bind BECLIN1, p22phox, and 14-3-3β important for RUBICON’s 
biological function (224). We did not observe any evidence that a truncated protein product is 
produced in the Rubicon knockout mice that we generated (data not shown). Moreover, 
heterozygous mice do not recapitulate the phenotype of Rubicon-deficient SLE prone mice, as 
might have been expected had we generated a dominant negative allele. Rubicon+/- MRL.Faslpr 
mice can produce antibodies to Sm antigen. In the setting of Cybb-deficiency, Rubicon 
heterozygosity did not ameliorate SLE renal disease. Therefore, it is unlikely that the CRISPR-
Cas9 strategy employed to make a Rubicon knockout mouse resulted in a dominant negative 
allele.  
Another significant finding is that myeloid IL-10 deficiency does not impact SLE 
pathogenesis in our system. As discussed in chapter 3, LysM-Cre has a mediocre efficiency in 
macrophages. It is possible that partial deletion of IL-10 in the myeloid compartment is not 
sufficient to modulate SLE. However, IL10+/-  MRL.Faslpr mice developed more severe renal 
disease and dermatitis compared to their IL-10 intact counterparts, making this explanation less 
likely (242). Therefore, IL-10 production downstream of LAP in macrophages is unlikely to be a 
dominant immune regulatory mechanism in MRL.Faslpr mice.  While macrophages do produce 
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IL-10 in murine lupus, the myeloid compartment is not the only cellular source of IL-10 in this 
setting. In addition to macrophages, T cells are major IL-10 producers in SLE prone mice (245). 
More specifically, IL-10 is predominantly generated by T regulatory cells and CD4+FoxP3- T 
cells (245). Taken together, it is thus likely that T cell derived IL-10 plays a more critical role in 
regulating SLE pathogenesis.  
The studies that we collectively present suggest that defective LAP is not the mechanism 
by which Cybb deficiency promotes autoimmunity. The lack of phenotype observed in SLE 
prone mice with myeloid specific IL-10 deficiency strengthens this conclusion. Importantly, and 
unexpectedly, our data implicate RUBICON as a novel mediator of systemic autoimmunity, a 
finding that requires further mechanistic study and may have therapeutic implications for SLE 
patients.   
4.6 MATERIALS AND METHODS 
Mice. IL-10fl/fl C57BL/6 mice (249) were backcrossed to the MRL.Faslpr strain for at least 9 
generations (245). Homozygosity for the lpr mutation was verified by PCR. LysM-Cre 
MRL.Faslpr mice were intercrossed with IL-10fl/wt MRL.Faslpr mice. Resulting LysM-Cre+/- IL-
10fl/wt MRL.Faslpr mice were then crossed with MRL.Faslpr IL-10fl/wt. To generate mice for 
experimental cohorts, we intercrossed LysM-Cre+/- IL-10fl/fl to IL-10lfl/fl.  This breeding allowed 
us to use littermate controls for each group. SLE pathology was assessed at 18 weeks of age. 
Generation of the Rubicon knockout mouse on the MRL.Faslpr background. Rubicon-deficient 
Rubicon-deficient MRL.Faslpr mice were generated by in vitro fertilization and CRISPR-Cas9 
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technology as previously described by replacing Asp188 with a premature stop codon (89). In 
brief, a sgRNA targeting exon 5 of Rubicon was selected and generated as described in chapter 
3. MRL.Faslpr pronuclear-stage zygotes were injected with capped Cas9 mRNA, a gRNA 
targeting the end of exon 5 and a 183-nucleotide-long ssODN that served as a repair template. 
Mice were genotyped by PCR amplification and RFLP analysis of the target locus. Amplified 
PCR products were subsequently cloned into a sequencing vector (NEB) and sequenced to verify 
correct targeting. 
To generate mice for experimental cohorts, we intercrossed: (1) Rubicon-/+Cybby/- X 
Rubicon-/+Cybb+/- , (2) Rubicon-/+Cybby+- X Rubicon-/+Cybb+/-, and (3) Rubicon-/+ X Rubicon-/+. 
This breeding produced littermate controls for each group. SLE pathology was assessed at 18 
weeks of age. 
 
Quantitative PCR. qPCR was used to measure IL-10 deletion efficiency as described in chapter 
3. 
 
Evaluation of SLE pathology. Refer to chapter 1 
 
Flow cytometry. Refer to chapter 1 
 
Autoantibody ELISAs. Refer to chapter 1 
 
Generation of bone marrow derived macrophages (BMDMs). Femurs, tibias, and iliac crests 
were harvested from MRL.Faslpr mice of indicated genotypes and bone marrow was isolated by 
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mortar and pestle. Cells were incubated in ACK (Ammonium-Chloride-Potassium) buffer for 
erythroid cell lysis. 10X106 bone marrow cells were plated on 100mm petri dishes in 10mL of 
complete DMEM (Gibco) media supplemented with 10% fetal calf serum and 30% L929 
macrophage colony stimulating factor (MCSF) conditioned media. Media was replaced after 3 
day of culture. On day 7, adherent macrophages were harvested, replated, and rested for 24 hours 
prior to experimental use.   
 
Induction of LAP and canonical autophagy. To induce canonical autophagy, peritoneal 
macrophages or BMDMs were subjected to starvation conditions (Earle's Balanced Salt Solution 
(EBSS)) or stimulated with Rapamycin (200nm) for 6 to 18 hours. Zymosan bioparticles 
(thermofisher) were added to macrophages cultures for 6 to 18 hours at a ratio of 8:1 
(particles/cell) to induce LAP.  
 
Immunoblotting. Cells were lysed in 2X llamelli’s buffer (Bio-Rad) supplemented with 5% 
beta-mercaptoethanol and heated to 95 degrees for 5 min.  Lysates analyzed by SDS-PAGE. 
Immunodetection was achieved using the following antibodies: LC3B (Cell Signaling; D11, 
1:1000), RUBICON (Cell Signaling; D9F7,1:1000), β-Actin HRP (Cell signaling; 8H10D10, 
1:10,000), Anti-Rabbit IgG HRP (Cell signaling, 1:10,000). Proteins were visualized by an ECL 
chemiluminescence reagent and imaged by a Protein Simple imager.  
 
Statistics. Refer to chapter 1 
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5.0  CONCLUSIONS AND FUTURE STUDIES 
5.1 SLE PATHOLOGY IS INDEPENDENT OF PADI4 AND ELANE 
In our studies, we used an in vivo genetic approach to assess the causative role for NETs in SLE. 
We targeted two distal conserved mediators required for NET formation, Padi4 and Elane in the 
MRL.Faslpr model. Neither Padi4 nor Elane deficiency improved SLE pathology, a finding also 
recently recapitulated in the pristane model of lupus (77). Moreover, pharmacological inhibition 
of PADs using Cl-Amidine had no effect in neutrophil recruitment or glomerular injury in two 
independent models of IC-FcγR mediated glomerulonephritis (133). Taken together with the 
reproducible finding that NADPH oxidase deficiency promotes SLE in humans (120-125, 179) 
and in multiple murine models (75, 89, 180, 250), the work that we present here do not support 
the hypothesis that NETs are the primary antigen source nor directly instrumental in mediating 
end-organ damage in lupus. Moreover, our findings have ramifications for the development of 
the Padi4 inhibitors that will soon enter clinical trials to treat patients with autoimmune diseases. 
Further, an important contribution of the current work is that it reveals a distinction 
between Padi4, Elane and Cybb-deficient lupus-prone mice, in that only the latter get 
exacerbated disease. As CYBB, ELANE, and PADI4 operate at distinct phases of NET 
formation, it remains possible that the aberrant products of presumably “frustrated” NET 
generation that would occur in the absence of each required protein might differ, in turn 
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accounting for the disparate disease phenotypes. As Cybb-deficiency leads to markedly 
exacerbated disease, the products of neutrophil death in the absence of CYBB could be uniquely 
immunogenic. Alternatively, though not exclusively, Cybb-deficiency might promote disease due 
to lack of a fundamental regulatory activity of CYBB in neutrophils (84, 85), macrophages (86), 
or another cell in the immune system (87, 88). This hypothesis was directly tested in chapters 3 
and 4. 
5.2 INHERENT DIFFICULTIES IN STUDYING NETS IN VITRO AND IN VIVO 
While there is a growing body of literature that links NET formation to SLE, much of this work 
was conducted in vitro and does not necessarily reflect in vivo disease. Part of the confusion may 
stem from technical issues:  it is difficult to prove presence of in vivo and in vitro NETs as no 
specific markers for NETs have been identified and NET-like structures can be generated by 
physical force (251). Moreover, antibodies used to assess histone citrullination are not 
necessarily specific (252). Exemplifying these issues, two recent concurrent publications by 
Ander’s and Yousefi’s groups (253, 254) describe contradictory roles for the receptor- 
interacting protein kinases in NET generation. We have had difficulty recapitulating robust NET 
formation in vitro by canonical NET inducing in mouse neutrophils, an issue also encountered by 
others groups (96). Employing a high throughput fixed cell and live cell imaging protocol, we 
had hoped to better define NETs and their unique features in SLE. Unfortunately, due to the 
aforementioned technical issues, we paused this line of investigation. In the future, we could 
employ in vivo imaging modalities in MRL.Faslpr mice with genetic deletions in the NET 
pathway, such as Cybb, to determine whether “frustrated” NET formation occurs in this setting. 
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Therefore, the genetic and pharmacologic in vivo model approach we report here, along with the 
consistent results obtained by targeting multiple genes in the NET pathway, provide evidence to 
seriously question the hypothesis that NETs promote SLE.  
5.3 THE CELL SPECIFIC ROLE OF CYBB IN SLE: PRELIMINARY 
CONCLUSIONS 
The studies that we present here, employing both a conventional bone marrow chimera approach 
and a novel chimera strategy to specifically delete Cybb in macrophages and neutrophils, 
demonstrate that myeloid Cybb deficiency is sufficient to exacerbate SLE pathogenesis. It is still 
unknown whether Cybb deficiency in the neutrophil or macrophage is the primary driver of lupus 
pathogenesis. This piece of the puzzle will point to the mechanism by which CYBB modulates 
lupus as discussed in chapter 3. We hypothesize: (1) The absence of CYBB in neutrophils may 
alter the way in which the neutrophil dies resulting in a more immunogenic form of cell death 
and (2) CYBB is critical for macrophages to engulf and degrade dying cells. These two 
hypotheses are not mutually exclusively and would both lead to the aberrant accumulation of 
autoantigen. To tackle this question, we employed the LysM-Cre and Mrp8-Cre MRL.Faslpr 
strains to delete the Cybb-floxed allele in macrophages and neutrophils or neutrophils only 
respectively. SLE was aggravated in both cohorts, albeit not to the degree of the global 
knockouts or the hematopoietic chimeras. Taken together, our preliminary studies indicate that a 
regulatory function of CYBB in the neutrophil is important for limiting systemic autoimmunity. 
The mechanism by which Cybb deficiency in neutrophils drives SLE remains to be elucidated 
and is an active area of investigation by our laboratory.  
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There are two explanations as to why conditional deletion of Cybb mediated by LysM-
Cre and Mrp8-Cre did not recapitulate the phenotype observed in either the Cybb global 
knockouts or the Cybb hematopoietic chimeras. First, LysM-Cre does not efficiently target 
macrophages (184), and therefore, we cannot rule out a contribution for macrophage CYBB 
SLE. The limitations of LysM-Cre observed by our group and others highlights the need to 
develop a Cre strain that is both efficient and specific at targeting macrophage populations. It is 
also possible that CYBB is exerting a regulatory function in another cell type of the immune 
system such as B cells and T cells. To address this possibility, we are investigating the role of B 
cell Cybb in lupus by harnessing a Cre-lox approach to specifically delete Cybb in B cells in the 
MRL.Faslpr model.  
5.4 RUBICON DEFICIENCY AMELIORATES SLE PATHOGENESIS 
To test the hypothesis that absence of CYBB drives SLE pathogenesis by preventing 
macrophages from degrading dead cell debris via a defect in LAP, we genetically deleted another 
molecule in the LAP pathway, Rubicon, in the MRL.Faslpr SLE model. Strikingly, Rubicon 
deletion in Cybb-deficient MRL.Faslpr mice reduced renal disease and increased the life-span of 
the cohort. Moreover, Rubicon deficiency reduced autoantibodies to RNA but not DNA related 
autoantigens. These findings mimic the phenotype observed in Tlr7-deficient SLE prone mice (2, 
3). It is a compelling hypothesis that Rubicon mediates lupus pathogenesis by augmenting TLR7 
function or trafficking of its ligands in B cells. We can determine whether Rubicon augments 
TLR7 function by assessing the responses of Rubicon-deficient B cells to TLR7 ligands in vitro. 
In the in vivo disease setting, we can test whether Rubicon deficiency protects Tlr9-/- MRL.Faslpr 
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mice that develop exacerbated lupus which is known to be dependent on TLR7 (2, 3). Similarly, 
we can take advantage of murine SLE models that are driven by Tlr7 overexpression, such as, 
Yaa mice. The relationship between RUBICON and TLR7 remains enigmatic and requires 
further investigation. 
It is still unknown in which cell type does Rubicon deficiency exert its protective effect(s) 
in SLE pathogenesis. The differential regulation of RNA and DNA autoantibody responses point 
to a B cell intrinsic mechanism. The cell specific role of RUBICON in SLE can be assessed by 
generating the Rubicon-floxed allele and crossing it to tissue specific Cre strains that are already 
backcrossed to the MRL.Faslpr background. CD19 Cre can be employed to specifically delete 
Rubicon on B cells in SLE prone mice, allowing us to assess B cell specific Rubicon deletion on 
autoantibody responses and clinical manifestations of lupus.  
Moreover, the studies presented here do not implicate LAP as a driver of SLE 
pathogenesis. Production of the immunoregulatory cytokine IL-10 by macrophages undergoing 
LAP is postulated to be a dominant mechanism constraining the anti-self response. IL-10 
deficiency did not alter the disease course in the MRL.Faslpr SLE model reinforcing our 
conclusions. Our findings are incongruous with prior observations in non-autoimmune prone 
C57BL/6 mice that develop a SLE-like disease with age in the absence of LAP components, 
including CYBB and RUBICON. It is possible that the opposing phenotypes observed in our two 
studies are a result of model systems employed. The SLE-like disease identified in LAP-
defective C57BL/6 mice may resemble an autoinflammatory syndrome as opposed to bonafide 
autoimmunity since histological SLE kidney disease was mild in these cohorts (90). It is 
imperative that the discrepancies between these two studies be resolved. Assessment of LAP 
components in additional murine models of SLE may be helpful in this regard. Importantly, our 
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work highlights RUBICON as a novel mediator of systemic autoimmunity. The mechanism by 
which RUBICON is protective in the setting of SLE remains to be explored and could represent 
a new druggable target for the treatment of lupus patients.  
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SELECTED LIST OF ABBREVIATIONS 
AFC   Antibody forming cell 
APC   Antigen presenting cell 
BMDM   Bone marrow derived macrophages 
CARD  Caspase activation and recruitment domains  
CGD   Chronic granulomatous disease  
Cl-Amidine  N-R-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide  
Cybb (nox2, gp91)  Cytochrome b-245, β polypeptide  
DAMP danger associated molecular patterns 
DC   Dendritic cell 
DTA    Diphtheria toxin fragment A 
Elane   Neutrophil elastase 
FcγR   Fcγ receptor 
GBM   Glomerular basement membrane 
IFN   Interferon 
IFNAR  Interferon-α/β receptor  
IL   Interleukin 
Interferon regulatory factor IRF 
LAP   LC3-associated phagocytosis  
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LC3    Microtubule-associated proteins 1A/1B light chain 3  
lyso-PS  Lysophosphatidylserine 
MPO   Myeloperoxidase 
NADPH   Nicotinamide adenine dinucleotide phosphate 
NCF   Neutrophil cytosolic factor  
NET   Neutrophil extracellular trap 
NFκB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
Padi4   Peptidyl arginine deiminase 4 
PIL   Pristane induced lupus  
PRR   Pattern recognition receptors  
PS   Phosphatidylserine 
ROS   Reactive oxygen species 
RPA   Reverse passive Arthus reaction 
Rubicon   RUN and cysteine rich domain containing beclin 1 interacting protein 
sgRNA  Single guide RNA 
SLE   Systemic Lupus Erythematosus 
SLEDAI  Systemic Lupus Erythematosus Disease Activity Index 
SM    Smith antigen  
ssODN   Single stranded oligodeoxynucleotides 
TLR   Toll like receptor 
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